国际动态
国际动态资讯
- 8/12 CRISPR-Generated Neuronal Cells May Serve as Brain Disease Models
- 8/12 Zealand takes PhII data to FDA after pitting diabetes drug against Novo’s incumbent
- 8/12 Battered and bruised, ProNAi Therapeutics drops PNT2258 completely
- 8/12 AstraZeneca Transcends Brexit Woes on Pound Slump, Rival’s Flop
- 8/12 Perennial dealmaker Zymeworks licenses new drug discovery platform
- 8/12 Zymeworks bags a protein engineering platform as it preps for an IPO
- 8/12 Venetoclax safe, shows promise in patients with acute myelogenous leukemia
- 8/12 Snippet roundup: Lilly pill slips, Mek inhibitors reach limit, Myriad buys
- 8/12 BRIEF-Pharma Mar to recruit total of 420 patients for PM1183 Corail study
- 8/12 Novartis Upends Early-Stage Drug Research
- 8/11 FDA updates draft guidance on premarket safety notifications for dietary supplement industry
- 8/11 AstraZeneca pours more money into the Moderna pot
- 8/11 Start small, think big: Genmab racks up a bispecific development deal with HIV specialist Gilead
- 8/11 Protocols: Infinity hunts up a buyer for its disappointing cancer drug duvelisib; Is Northwest Bio finally broke?
- 8/11 BioLineRx Names Philip A. Serlin as Chief Executive Officer
- 8/11 BioLineRx Reports Second Quarter 2016 Financial Results
- 8/11 21 Hospitals Across China to Adopt Watson for Oncology to Help Physicians Personalize Cancer Care
- 8/11 CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody, CAN-017, for Esophageal Squamous Cell Cancer
- 8/11 Beyond CRISPR: A guide to the many other ways to edit a genome
- 8/11 Replications, ridicule and a recluse: the controversy over NgAgo gene-editing intensifies
- 8/10 BMS buys back early oncology rights from Asia partner
- 8/10 Medivation eyes PARP-PD-1 cocktail; still no word on pidilizumab future
- 8/10 Why Abbvie might think twice before exercising Ablynx option
- 8/10 A new Valeant starts to take shape, and it's still not pretty
- 8/10 Heron Announces FDA Approval of SUSTOL® Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
- 8/10 Eisai, Biogen move Alzheimer’s drug into Phase III
- 8/10 Oncolytics Reports Additional Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer
- 8/10 Researchers find new info on ovarian cancer drug resistance
- 8/10 Lilly breast cancer drug stumbles, but trial continues
- 8/10 Nanotech Drug Delivery Expands Its Range of Applications
- 8/8 Bristol-Myers' High-Risk Opdivo Lung Cancer Study Shows Challenges Of Clinical Trials
- 8/8 Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease
- 8/8 Celgene backs Cleave in $37M financing to tame protein homeostasis
- 8/8 Racing past a wounded Juno, Kite aims to file lead CAR-T for OK by end of 2016
- 8/8 Juno throws down the multiple myeloma gauntlet to Bluebird
- 8/8 Novartis’ fevipiprant hailed a “game-changer” in asthma treatment
- 8/8 US clears Merck’s Keytruda for head and neck cancer
- 8/8 BRIEF-Oncbiomune Pharmaceuticals provides update on latest data from Phase 1 trial of Proscavax
- 8/8 Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study
- 8/8 BioLineRx Signs Second Clinical Immuno-Oncology Collaboration to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
- 8/5 Bristol-Myers Executives: We Took A Bold Risk With Failed Lung Cancer Study
- 8/5 Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
- 8/5 AbbVie Files Patent Suit Over Amgen’s Copy of Humira
- 8/5 The new buzz in R&D, blockbuster work on a budget and why what’s dead may never die
- 8/5 A key trial for a Bristol-Myers cancer drug fails in a ‘major surprise’
- 8/5 Bristol swings for the fences and strikes out
- 8/5 Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study
- 8/5 Juno Licenses BCMA from MSK, Eureka Therapeutics
- 8/4 Is Prediabetes An Epidemic Or A Creation Of Drug Companies?
- 8/4 Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma
- 8/4 Regeneron makes a blockbuster case for its PhIII drug pipeline
- 8/4 Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis
- 8/4 Study shows long-term benefit with ReNeuron’s stroke therapy
- 8/4 Speculation of Novartis takeover boosting AstraZeneca shares
- 8/4 One Step Forward But Two Steps Back In Huntington's
- 8/4 Roche pulls plug on Inovio deal
- 8/4 Biogen not pursuing a sale: source
- 8/4 Research: Innovation Suffers When Drug Companies Merge
- 8/3 Biogen Is a Takeover Target but Don't Ignore the Risks
- 8/3 Israel's Ornim raises $20M for noninvasive continuous blood-flow monitor
- 8/3 Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark
- 8/3 ASCT Retains Key Role in Myeloma Care
- 8/3 HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial
- 8/3 Takeda/Tigenix’ stem cell therapy hits targets in Crohn’s trial
- 8/3 US breakthrough status for Novartis’ breast cancer drug
- 8/3 Astrazeneca might have created value but now it needs to deliver
- 8/3 How To Accelerate The Search For Alzheimer's Drugs
- 8/3 12 Serial Entrepreneurs Who’ve Created Value in Biotech Over, and Over, Again
- 8/2 Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
- 8/2 Amgen to Develop Advaxis' Preclinical Cancer Immunotherapy ADXS-NEO
- 8/2 Novartis partner BioLineRx in-licenses NASH drug after joint evaluation
- 8/2 BioRegnum: The miracle drug story that just won’t die
- 8/2 Analyst: Pfizer scraps its oral PCSK9 ‘Holy Grail’ drug
- 8/2 PharmaMar Initiates a Pivotal Phase III with PM1183 in Combination with Doxorubicin in Patients with Small Cell Lung Cancer
- 8/2 Regeneron, Adicet Partner to Research Engineered Immune-Cell Therapeutics
- 8/2 Biogen gains sharply on Merck, Allergan takeout rumors
- 8/2 Lupin to buy 21 branded drugs from Japan's Shionogi
- 8/1 Theranos Presents Data On New Blood Test Machine, Remains Mum On Previous Technology
- 8/1 Shire’s NASH candidate gains FDA fast track as it races into PhII
- 8/1 Biogen pays $75M to Ionis on early PhIII antisense results
- 8/1 Pfizer boosts its gene therapy work, bags upstart Bamboo in $645M buyout deal
- 8/1 Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin)
- 8/1 MEI Pharma's Pracinostat Receives BTD for Treatment in Combination with Azacitidine
- 8/1 Tokai Pharmaceuticals takes ax to 60% of workforce after PhIII blowout
- 8/1 Data From RNAi In Hep B And A Novel Dermatitis Antibody
- 8/1 Calls grow for China to bring in newer HCV therapies
- 8/1 Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- 7/29 A Proposal To Spur Pharma R&D Investment Into Antibiotics For 'Superbugs'
- 7/29 Upcoming events – Data from RNAi in Hep B and a novel dermatitis antibody
- 7/29 Seres shares crash after microbiome drug flunks PhII
- 7/29 The biopharma week in review: Thumbs Up, Thumbs Down
- 7/29 Bristol-Myers takes a commanding lead over Merck in the first stretch of a blockbuster race
- 7/29 Japan’s Takeda Sees $725 Million in Costs From R&D Revamp
- 7/29 NewLink Genetics to Eliminate 100 Jobs, 43% of Workforce
- 7/29 5 Things You Must Know Before the Market Opens Friday
- 7/29 What Are Analysts Saying About Q2 At Biotech's Big 4? Amgen, Biogen, Celgene, Gilead
- 7/29 AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
- 7/28 Rare Diseases, Big Sales: A Look At BioMarin, Biotech's $15 Billion Next Big Thing
- 7/28 Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
- 7/28 Fosun Pharma to Acquire Gland Pharma for Up to $1.26B
- 7/28 Gilead hep C drug prices blamed for England’s health service rationing treatment
- 7/28 Q2 clear-out sees AstraZeneca dump gastric cancer, NASH PhIII studies
- 7/28 Pointing to a cure, BioMarin reports impressive trial results for hemophilia A gene therapy
- 7/28Genelux Initiates Two Clinical Trials of GL-ONC1 in Ovarian Cancer and Solid Organ Cancers with Leading Oncology Institution
- 7/28 The biggest winners and losers in the 2016 game of blockbusters
- 7/28 GamaMabs Pharma starts phase Ia/Ib study of first-in-class monoclonal antibody GM102 in advanced gynecological cancer
- 7/28 FDA approves Adlyxin to treat type 2 diabetes
- 7/28 Glaxosmithkline, Johnson & Johnson in $229M pact on IL-33R antibody for asthma
- 7/28 TauRx touts second chance to prove success
- 7/27 MIT researchers develop hydrogel patch to deliver cancer combo
- 7/27 Korean Scientists Develop Micrometer-sized Robots for Cancer Treatment First in The world
- 7/27 pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial
- 7/27 Sangamo gene therapy for hemophilia shows positive results in mice, monkeys
- 7/27 Merck shocks ALK by returning rights to allergy immunotherapies
- 7/27 TauRx takes a slice of positive data and claims success after a failed PhIII Alzheimer’s study
- 7/27 Combining Ipilimumab with local treatments improved survival for patients with melanoma
- 7/27 Beefing up its respiratory pipeline, GlaxoSmithKline bags J&J drug in $230M deal
- 7/27 Lilly Turns From One Company Veteran to Another for New CEO
- 7/27 Pfizer bags a Langer platform, buys Bind assets with a $40M bid
- 7/26 Tokai Pharma Shutters Prostate Cancer Drug Trial Early, Shares Crumble
- 7/26 Triumvira targeting cancer with customized T cells
- 7/26 Newron to resubmit troubled Parkinson’s drug to FDA; abuse risks cleared
- 7/26 X-Chem and AbbVie Enter into Multi-Target Drug Discovery Partnership
- 7/26 Ex-Amgen team nabs $14M from Merck, Gates Foundation for cheap biologics
- 7/26 The Nanotechnology Startup Challenge in Cancer Announces 10 Winning Teams to Launch Startups around Promising Inventions
- 7/26 Diagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology
- 7/26 BMS, Janssen Biotech to Partner on Immuno-Oncology Trial
- 7/26 Microneedle can monitor drugs in bloodstream without pain or blood draws
- 7/26 J&J, Genmab bag breakthrough status for Darzalex, shortening route to second-line use
- 7/25 A New Look At The Most Innovative Pharma Companies (And Whether They Are Sustainable) -- Part I
- 7/25 Alnylam Announces New Positive Interim Phase 1 Results for Fitusiran, a Once-Monthly Investigational RNAi
- 7/25 AbbVie, Bristol-Myers to combine checkpoint inhibitors, Rova-T in cancer trials
- 7/25 Tricida raises $55M, to get kidney disease data this year
- 7/25 Pfizer, NEA-backed rare disease startup bumps up Series A to $42M
- 7/25 Malaria drug may help in cancer fight, early research finds
- 7/25 BIND Therapeutics Announces Two Bidders Join Pfizer’s Stalking Horse Bid in Auction for BIND’s Assets
- 7/25 PTC faces a delay in Europe for controversial Duchenne drug
- 7/25 Eyeing an IPO, Alzheon looks to raise $100M for a “derisked” Alzheimer’s PhIII
- 7/25 Value-Based Drug Pricing: Watch Out for Side Effects
- 7/22 Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- 7/22 FDA Delays Decision on Merck C. difficile Candidate, Seeks More Data
- 7/22 German startup raises $34M for first-in-class complement inhibitor
- 7/22 What’s the hottest biotech R&D field in venture investing?
- 7/22 Pfizer/Spark team gets a ‘breakthrough’ in gene therapy alliance
- 7/22 Scientists hunt 'anti-evolution' drugs in new cancer fight
- 7/22 Chinese Scientists Plan First Human Test With Gene Editing Tool
- 7/22 Puma Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib)
- 7/22 Could Antibiotics Be a Potential New Treatment Strategy for Alzheimer’s?
- 7/22 The unsung heroes of CRISPR
- 7/22 These drugs could cut American health costs by $250 billion (if only we could take them)
- 7/22 Late-stage study shows biosimilar candidate ABP 980 non-inferior to Roche's Herceptin
- 7/20 DNA pioneer James Watson: The cancer moonshot is ‘crap’ but there is still hope
- 7/20 Biohaven commences clinical testing of BHV-4157
- 7/20 Now cancer-free after Keytruda combo, Poison drummer Rikki Rockett ready to spread the word
- 7/20 Novartis CEO predicts drug pricing overhaul in U.S. after the election, whoever wins
- 7/20 Antidepressant target discovery could lead to gene therapy
- 7/20 Preclinical gene therapy play Audentes trades up on $75M IPO
- 7/20 By the numbers: 2-year tally of Celgene’s biotech partnership deals tops $3B in cash
- 7/20 Another Derek Lowe post points to more R&D cuts at AstraZeneca, this time in Boston
- 7/20 Arbutus Reports Topline Results from TKM-PLK1 HCC Clinical Trial
- 7/20 Oncorus Bags $57M, Touts Next-Gen Take on Cancer-Fighting Viruses
- 7/19 For Liquid Biopsy, Size Matters
- 7/19 Ionis outlicenses antisense GI drug to Janssen as the pharma posts Q2
- 7/19 Novartis’ campaign to sweep biosimilar approvals hits a setback
- 7/19 Celgene signs Jounce as its new biotech star in $2.6B ‘immuno-oncology 2.0’ pact
- 7/19 ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
- 7/19 Brainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial
- 7/19 GSK Launches First ResearchKit Study by a Major Pharmaceutical Company
- 7/19 Evoke Pharma Lead Candidate EVK-001 Fails Phase III Trial
- 7/19 Revisiting CAR T-Cells for Treating HIV Shows Promise
- 7/19 Which big biopharma companies put R&D as their top priority?
- 7/19 Rapamycin’s secrets unearthed: From its exotic origins to its revival as a potential antiaging compound, rapamycin continues to fascinate
- 7/15 FDA approves first intraocular lens with extended range of vision for cataract patients
- 7/15 ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
- 7/15 Biotech VC: On track for second-highest year in 2016
- 7/15 Xbiotech Responds to ESMO, Other Critics of Phase 3 Cancer Data
- 7/15 Q2 venture investing slows a tad, but the big money still flows into biotech
- 7/15 MRCT offloads Keytruda royalty rights to DRI, raising $150M for new research
- 7/15 FDA review details suicides, cardio risks linked to Valeant’s $100M drug brodalumab
- 7/15 Juno Therapeutics Adds Adenosine Receptor Antagonist Through Acquisition of RedoxTherapies
- 7/15 'Smart' nanoparticle called PEARLs a promising gem to target, treat tumours
- 7/15 Investigator-Sponsored Plinabulin Combination Study for Metastatic NSCLC Granted FDA Clearance to Enroll Patients
- 7/14 Researchers to see, track patient data using new 23andMe platform
- 7/14 Kite, analysts unfazed by Juno trial issues, say low-dose fludarabine safe
- 7/14 Boehringer strikes deal to develop protein-degrading cancer drugs
- 7/14 Avacta, Glythera Partner to Develop Alternatives to ADCs
- 7/14 And then there were 4: Juno adds another victim in CAR-T death tally
- 7/14 Immunotherapy drugs show promise in a range of advanced blood cancers
- 7/14 Santhera’s Duchenne drug hits a roadblock at the FDA, and one analyst sees another bad sign for Sarepta
- 7/14 Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- 7/14 Antipsychotic drug also relieves nausea from cancer chemotherapy
- 7/14 Back to the Future in the Quest for Affordable Cancer Care
- 7/13 Juno being sued over leukemia drug study
- 7/13 Novartis cancer drug to be tested for Parkinson’s disease
- 7/13 Biosimilars go 2-0 in an FDA double-header favoring Novartis, Amgen
- 7/13 The 15 top R&D spenders in the global biopharma business
- 7/13 Targeted Nanosystem Drug Delivery Method, A New Drug Carrier Discovered
- 7/13 Gilead cut U.S. tax rate even as U.S. sales soared, report says
- 7/13 Merck vet Michael Rosenblatt joins R&D exodus to the startup world
- 7/13 First evidence that PD-1 antibody could help men with metastatic prostate cancer
- 7/13 BRIEF-Ziopharm plans for Phase I clinical trial with CD33 CAR-T cell therapy targeting acute myeloid leukemia
- 7/13 Phase III study of cabozantinib for advanced prostate cancer fails to enhance overall survival
- 7/12 Atara Bio Doses First Patient for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes in EBV-Associated Lymphomas and Lymphoproliferative Disorders
- 7/12 Experimental Drug Dramatically Reduces Post-Partum Depression In Small Study
- 7/12 Sage soars on small postpartum depression study results
- 7/12 Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
- 7/12 Repatha Approved for Single Monthly Injection
- 7/12 Trovagene and USC Norris Comprehensive Cancer Center Collaborate on Trovera™ ctDNA Liquid Biopsy Tests
- 7/12 Shire finally gains FDA approval for delayed dry eye drug lifitegrast
- 7/12 With Bugs As Drugs, Evelo CEO Plans Immune, Cancer Trials in 2017
- 7/12 Merck to cut 360 R&D jobs, close one facility, and expand elsewhere
- 7/11 Amgen picks up an edge for Repatha in duel with Sanofi and Regeneron
- 7/11 FDA approves first MRI-guided focused ultrasound device to treat essential tremor
- 7/11 FDA narrowly defines the ability of compounders to make approved medicines
- 7/11 Sucampo Provides Update on Cobiprostone Development Program
- 7/11 AstraZeneca share price subdued as pharmco mulls $10bn bid for Medivation
- 7/11 Immunotherapy Slashes Rheumatoid-Associated Heart Disease Risk
- 7/11 Celyad Enters into License Agreement with ONO PHARMACEUTICAL to Develop Allogeneic NKR-2 T-cell Immunotherapy
- 7/11 Celyad inks $300M Ono I/O deal, calls out differences between it and Juno
- 7/11 Sorrento nabs PD-1 deal with Servier
- 7/11 In Juno patient deaths, echoes seen of earlier failed company
- 7/11 ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial
- 7/8 FDA approves Differin Gel 0.1% for over-the-counter use to treat acne
- 7/8 Big Data Shows Cancer Cell Lines Reflect Patient Tumor Mutations
- 7/8 Gene therapy could lead to better, light-based cochlear implants
- 7/8 Elizabeth Holmes Has Been Banned. What Does That Mean For Theranos?
- 7/8 Theranos founder and CEO Holmes banned from CA lab operations for 2 years
- 7/8 Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences
- 7/8 Kite Pharma Completes Enrollment of All Patients with DLBCL in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1)
- 7/8 Are patient deaths in the Juno cancer trial just a ‘bump in the road’?
- 7/8 Juno Therapeutics' Lead Drug Trial Halted As Patients Die From Neurotoxicity
- 7/8 Juno Therapeutics Stops Trial Of Cancer-Killing Cells After 3 Patient Deaths
- 7/7 Bankrupt biotech Bind eyes $20M sale to Pfizer
- 7/7 More Cancer Mutations May Be Good for Immunotherapy Patients
- 7/7 Bio-Techne shells out $250M for Advanced Cell Diagnostics
- 7/7 Liquid Biopsy Predicts Colon Cancer Recurrence
- 7/7 Janssen Provides Webcast Presentation on Phase 3 data for DARZALEX® (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio
- 7/7 Seres takes first synthetically designed microbiome drug into the clinic to hit bigger markets
- 7/7 The Importance of Biomarkers for Cancer Immunotherapy
- 7/7 Two Drugs 'Graduate' From Novel I-SPY 2 Breast Cancer Trial
- 7/7 Obama Seeks To Make Mark On Genetic Medicine
- 7/7 FDA advances Precision Medicine Initiative by issuing draft guidances on next generation sequencing-based tests
- 7/6 Carmot Therapeutics Enters into Discovery Collaboration with Genentech
- 7/6 Fitbit partners with institute for breast cancer research
- 7/6 FDA Grants Special Protocol Assessment to Advaxis’ Phase 3 Study of AXAL in Patients with Cervical Cancer
- 7/6 XBiotech Plunges on Results of Colorectal Cancer Drug Trial
- 7/6 Syndax Expands Pipeline With Exclusive License Agreement for UCB’s CSF-1R Antibody Program
- 7/6 Pfizer, German Merck start first-ever PhIII PD-L1 combo trial for ovarian cancer
- 7/6 With new CEO’s dealmaking and price-hiking past, can Valeant change its spots?
- 7/6 Medivation plans a bidding war as it rejects Sanofi’s sweetened bid
- 7/6 JHU team demystifies 'one-two punch' that causes Alzheimer’s disease
- 7/6 FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
- 7/1 Forcing Fat Cells to Burn Calories
- 7/1 Engineered T Cells Police the Immune System, Eliminate Its Bad Apples
- 7/1 Array BioPharma Submits Binimetinib New Drug Application to U.S. FDA
- 7/1 Ampio shares in retreat on second failed osteoarthritis PhIII
- 7/1 Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer
- 7/1 Novartis Shanghai R&D center to help meet nation's health needs
- 7/1 Single-asset biotech Altos gains Takeda R&D backing; future takeover promise
- 7/1 Pfizer looks to regain lost ground with boco
- 7/1 Biotech's Top 5 Losers, And Winners, From Q2 2016
- 6/30 Top Officials Aim To Reshape The FDA To Prepare For 'Avalanche' Of Cancer Products
- 6/30 Protein cages for drug delivery
- 6/30 Anti-PD-L1 Immunotherapy Shows Response in Microsatellite-Stable Metastatic Colorectal Cancer in Combination with MEK Inhibition
- 6/30 Leap Therapeutics Presents Positive Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer
- 6/30 Group of rare blood cancers respond to new treatment pioneered by Stanford physician
- 6/30 PARP Inhibitors Come Through
- 6/30 As Tesaro jumps 108%, Medivation can raise its price, and even Clovis climbs
- 6/30 GSK, Pfizer, AbbVie back next-gen integrin drugs in $52M Series A
- 6/30 Pfizer, GSK And AbbVie Join $51.5M Bet On Computational Drug Discovery At Morphic Therapeutic
- 6/30 Intra-Cellular Therapies Reports Completion of Enrollment of ITI-007-302 Phase 3 Clinical Trial for the Treatment of Schizophrenia
- 6/30 BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317
- 6/30 Strong support for further investigation of the benefit of immune-checkpoint blockade in SCLC
- 6/29 A Proposal To Spur Pharma R&D Investment Into Antibiotics For 'Superbugs'
- 6/29 Can Esperion Therapeutics Ever Regain Wall Street's Trust?
- 6/29 FDA approves implantable device that changes the shape of the cornea to correct near vision
- 6/29 FDA issues new draft guidelines for ‘appearance’ of conflicts of interest
- 6/29 Johns Hopkins researchers target Parkinson’s disease protein with FDA-approved oncology drug
- 6/29 Galena Biopharma Discontinues NeuVax™ Phase 3, based on Independent Data Monitoring Committee Recommendation
- 6/29 Moderna Gets $200M More, Deepens Merck Ties With New Cancer Pact
- 6/29 Prolific biotech entrepreneur commits cash to Evotec’s NASH program
- 6/29 Tesaro Shares Surge 82% Because Drug Slows Ovarian Cancer
- 6/29 Tesaro’s PARP ovarian cancer drug hits PhIII goal; prepares to file
- 6/29 Cascadian Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer
- 6/29 BRIEF-Bayer says regorafenib improves survival in liver cancer patients
- 6/29 Lannett Sues FDA Over Temozolomide Capsules ANDA Approval Rescission
- 6/28 Roche's MS med ocrelizumab hits FDA fast track, eyeing earlier-than-expected launch
- 6/28 FDA approves Epclusa for treatment of chronic Hepatitis C virus infection
- 6/28 Merck KGaA, Pfizer help RNA modification biotech to £12M Series A
- 6/28 Roche’s new multiple sclerosis drug set for early FDA approval
- 6/28 Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration
- 6/28 Novartis and Xencor enter into bispecific antibody agreement
- 6/28 Pfizer to invest $350 million in China biotech hub, first in Asia
- 6/28 Regulus craters after FDA slaps a hold on hep C RNA drug following 2nd case of jaundice
- 6/28 A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle
- 6/28 China's biopharma boom at tipping point for growth, WuXi's Li says
- 6/27 Marijuana-Based Drug Helps Kids With Rare Forms Of Epilepsy In Studies
- 6/27 GW Pharma Marijuana Drug Confirms Seizure Benefit in Second Pivotal Trial
- 6/27 Puma Biotechnology Submits MAA for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
- 6/27 Advanced Accelerator Applications Announces FDA Priority Review for Lutathera
- 6/27 Ipilimumab plus T-VEC shows promise for metastatic melanoma
- 6/27 After 190 Tries, Are We Any Closer to a Cure for Alzheimer’s?
- 6/27 Reality check from Eric Lander: Majority of cancer cures will take decades
- 6/27 The Zerhouni rule: “Every company that acquires a platform company kills it.”
- 6/27 VM BioPharma enters gene therapy pain candidate into PhIII
- 6/27 Opdivo Receives Breakthrough Therapy Designation from U.S. FDA for Advanced Form of Bladder Cancer
- 6/24 New cell-based therapy to support stem cell transplantation in patients with high-risk blood cancer
- 6/24 Synthesizing Error-Free DNA from RNA
- 6/24 Pharmalot, Pharmalittle: Will Brexit force European drug regulators to leave London?
- 6/24 Uncertainty for biotech as U.K. exits EU, Prime Minister to resign
- 6/24 How to save 28,000 heart patients a year? Use Novartis' Entresto, JAMA says
- 6/24 Heart attack death increased by more than 50 percent for diabetes patients
- 6/24 Medivation slams Sanofi’s ‘misleading’ claims as merger saga continues
- 6/24 Oncology Drug Startup Hengrui Therapeutics Raises $100M
- 6/24 AstraZeneca, Teva Resolve Their Patent Row Over Diabetes Product
- 6/24 ABPI says UK vote to leave EU poses "immediate challenges" for pharmaceutical industry
- 6/24 U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective
- 6/23 Expert Update on Cancer Stem Cells and Cancer Stem Cell Inhibitors in Gastrointestinal Cancers
- 6/23 Cellectar Biosciences Announces NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer
- 6/23 Epizyme nabs combo trial deal with Genentech for NHL candidate
- 6/23 Incyte shrugs off trial failures with Merck PD-1/epacadostat tie-up
- 6/23 Cerulean Announces First Patient Dosed in Phase 2a Expansion Stage Evaluating CRLX301 in Patients with Advanced Solid Tumors
- 6/23 NEA leads $44M round to get Stanford neurodegenerative spinout Annexon into the clinic
- 6/23 The Growing Role of CROs in Cancer Drug Development
- 6/23 Rates of nonmedical prescription opioid use and opioid use disorder double in 10 years
- 6/23 Low doses of common cancer drug may promote cancer spread
- 6/22 Novo's Tresiba hits the airwaves with new TV campaign
- 6/22 Targeting Glycans Puts Icing on T-Cell Therapy
- 6/22 More health plans want to pay for drugs based on patient outcomes
- 6/22 Existing drug could prevent BRCA1-positive breast cancer
- 6/22 Expert Discusses What's Next for Opdivo in Kidney Cancer: Not only is Opdivo changing the way RCC is being treated
- 6/22 Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program
- 6/22 Is Opko Health a Buy Now That Rayaldee Is Approved?
- 6/22 Existing diabetes drug shows effectiveness against chronic liver disease
- 6/22 Birth Control via App Finds Footing Under Political Radar
- 6/22 Supreme Court decision a win for generic-drug makers fighting patents
- 6/21 The Way To Doctors' Prescription Pads Is Through Their Stomachs
- 6/21 Curis Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule Drug Candidate to Target Immune Checkpoints
- 6/21 Opko up on first FDA approval in chronic kidney disease associated indication
- 6/21 Rice University lab synthesizes new cancer fighter: Thailanstatin A disrupts disease by inhibiting DNA-editing machinery
- 6/21 BRIEF-Immune Pharmaceuticals data shows that ceplene enhances response to anti PD-1 AND ANTI-PD-l1 immune checkpoint inhibitors
- 6/21 Wave gains FDA orphan designation for Huntington’s candidate
- 6/21 Team Funded By Billionaire Sean Parker Aims To Be First To Use CRISPR Gene Editing In People
- 6/21 NewLink Genetics cuts staff after drug trial failure
- 6/21 GlaxoSmithKline PLC FULFIL Study Results Closed Triple EU
- 6/21 Biotech Stocks Tumble in Longest Selloff in Two Decades: Chart
- 6/21 HCV and HIV: shared challenges, shared solutions
- 6/20 A Market-Based Proposal For Controlling Drug Prices
- 6/20 A Novel, Targeted Drug Yields Promising Results In Stomach And Esophageal Cancer
- 6/20 Circassia sinks as key allergy drug fails PhIII, pipeline under pressure
- 6/20 Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
- 6/20 After failures and partnership breaks, Endocyte CEO retires
- 6/20 Epizyme Touts Early Data From Key Trial Of Blood Cancer Drug
- 6/20 Japan's Mitsubishi Tanabe files for ALS drug edaravone in U.S.
- 6/20 Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers
- 6/20 Oncternal Receives Fast Track Designation for TK216 in Relapsed or Refractory Ewing Sarcoma
- 6/20 Merck's Edge on Bristol-Myers Won't Last
- 6/20 Surrogate End Points Are Poor Predictors of Survival in Cancer Drug Approval
- 6/20 Pharma employees significantly favor Hillary Clinton with contributions
- 6/17 Something May Be Working At Theranos, But You Don't Know What It Is
- 6/17 BRIEF-Ariad initiates submission of NDA for Brigatinib to FDA ahead of plan
- 6/17 BioMarin climbs on rumors it may be Sanofi's Medivation backup
- 6/17 Takeda joins Celgene on M2Gen’s clinical and molecular cancer data sharing program
- 6/17 BRIEF-Oncology Venture's immuno-oncology drug APO010 gets EUROSTARS grant
- 6/17 Bristol's Opdivo-Yervoy melanoma combo wins speedy thumbs up from NICE
- 6/17 Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program
- 6/17 Health Plans Are Interested in Tying Drug Payments to Patient Outcomes
- 6/17 Cell Medica, Baylor partner on next-gen CAR-T cancer therapies
- 6/17 MorphoSys Reports Clinical Case of a Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission of MOR208 Treatment
- 6/17 Diversity and Inclusion: A Pharma 50 Perspective
- 6/16 Visualizing T-Cells in Action
- 6/16 Pharma loses one battle over drug take-back programs, but wins another
- 6/16 Roche's Gazyvaro cleared for follicular lymphoma in Europe
- 6/16 Medivation's Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse Intrinsic Pontine Glioma (DIPG)
- 6/16 Merck-Bristol showdown awaits as Keytruda scores in 1st line NSCLC
- 6/16 Merck’s KEYTRUDA® Demonstrates Superior PFS and OS Compared to Chemotherapy as First-Line Treatment in Patients with Advanced NSCLC
- 6/16 Therapy focus – First-line lung cancer is an Opdivo vs Keytruda showdown
- 6/16 UniQure slides toward historic lows after its hemB gene therapy goes up against Spark
- 6/16 In rare IPO by a VC shop, Draper Esprit raises £102M
- 6/16 Mersana pushes fundraising past $120M, takes aim at the clinic
- 6/15 FDA beefs up warnings on J&J, AZ SGLT2 meds, leaving Lilly and BI the happy exception
- 6/15 Nanotechnology Tool Allows Detailed Study of Proteins in Living Cells
- 6/15 Biotech employee charged with insider trading based on study results
- 6/15 Pfizer-backed dermatology player Ziarco looking to land buyout bid: Bloomberg
- 6/15 CAR T-cell Therapy: Getting a Handle on Toxicity
- 6/15 Treating 'Out-of-the-Box' Melanoma Patients With Anti-PD-1s
- 6/15 FDA's Oncology Leader Sends The Wrong Message On Immuno-Oncology Drug Research
- 6/15 Pfizer's Ibrance and next generation CDK4/6 inhibitors in breast cancer – KOLs speak out
- 6/15 Infinity to cut staff, re-examine AbbVie partnership following disappointing Phase II duvelisib results in lymphoma
- 6/15 Which Diet Drug Works Best? It May Depend on You
- 6/14 Reduce CV events, check. Now, Lilly, BI's Jardiance shows it can cut kidney disease risk, too
- 6/14 Infinity Pharma to cut 46 researchers after cancer drug trial disappoints
- 6/14 FDA approves AspireAssist obesity device
- 6/14 Marathon hopes to succeed where others have fallen with Duchenne NDA
- 6/14 Celator Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk AML
- 6/14 Shire picks up Pfizer’s experimental bowel disease drug
- 6/14 The Mystery of ALS Patients Who See Improvement
- 6/14 More clinical trials are succeeding for the first time in years
- 6/14 FDA overrides adcomm, shoots down KemPharm’s opioid
- 6/14 Study suggests benefits of statin therapy in older adults may be "exaggerated"
- 6/13 What's the buzz at ADA? Here's your rundown, with Merck, Pfizer, Sanofi, Novo and more
- 6/13 Merck's Lantus biosim MK-1293 gets closer to U.S. nod with new PhIII data
- 6/13 Personalized Medicine Study Improves Connection between Genomic and Proteomic Variation
- 6/13 Marinus sinks as seizure drug fails PhIII, jettisons program
- 6/13 A16z’s $200M biotech fund backs liquid biopsy upstart Freenome
- 6/13 Is Biden's cancer 'moonshot' initiative just creating new 'silos'?
- 6/13 FDA ‘breakthrough’ tags for Shire’s rare GI drugs
- 6/13 Pfizer's Antibody-based drug inotuzumab ozogamicin helps 'bridge' leukemia patients to curative treatment
- 6/13 FDA’s Pazdur chides biopharma for falling into an I/O rut
- 6/13 Former Dendreon CEO Secures $48M For Cancer Immunotherapy Startup
- 6/10 Bill Gates Says Gene Drives To Eradicate Some Mosquito Species Could Be Ready In Two Years
- 6/10 Regulator says too many drugmakers chasing same cancer strategy
- 6/10 GBT jumps after PhI/II sickle cell data allay durability doubts
- 6/10 New Phase 3 Data Show Jakafi® (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV)
- 6/10 Merck bags PhIII-bound Afferent Pharma in $1.25B deal
- 6/10 BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor ALL
- 6/10 FDA panelists chide Merck, but ultimately back approval of C. diff drug
- 6/10 Daratumumab Significantly Extended PFS in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
- 6/10 Amgen's experimental drug erenumab significantly cuts migraine days in mid-stage study
- 6/10 These Are the Most Promising Experimental Cancer Drugs
- 6/10 Decision Resources Group Analysts Highlight Key Trends Stemming from ASCO's 2016 Annual Meeting
- 6/8 Another Strike Against TV Drug Ads: Opioid-Induced Constipation
- 6/8 Boston Startup Raises $100 Million To Use Synthetic Biology To Design Microbes For Industry
- 6/8 GSK sets its sights on triple-combo-land with bumped-up COPD app
- 6/8 The first approval for Avastin in combination with another targeted therapy
- 6/8 'Oxygen' drink to battle cancer
- 6/8 GSK, J&J’s RA drug pulls off clean sweep of major endpoints in PhIII trial
- 6/8 Takeda to Develop Theravance's EFI Candidate TD-8954
- 6/8 12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting
- 6/8 FDA panel recommends approval of Teva’s abuse-deterring opioid, despite reservations
- 6/8 Gilead won’t have to pay $200 million in patent case because Merck lawyer lied
- 6/8 Here's What's Next For Cancer-Killing T-Cells After Strong ASCO Showings
- 6/3 Hikma receives FDA approval for Ketamine Hydrochloride Injection
- 6/3 BUZZ-India's Natco Pharma surges on tentative FDA nod for cancer drug
- 6/3 China corruption watchdog eyes CFDA, health ministry
- 6/3 Crizotinib Demonstrates Clinical Benefit in Phase II Study with ROS1-Positive Non-Small Cell Lung Cancer
- 6/3 Teva migraine patch gets close FDA scrutiny for causing burns and scarring
- 6/3 Seattle Children's T-Cell Immunotherapy for Children With Relapsed Leukemia Shows 93% Complete Remission Rate
- 6/3 A New CRISPR System for RNA
- 6/3 Investigational immunotherapy drug shrinks tumors in high-risk neuroblastoma patients
- 6/3 The FDA updates expanded access drug rules, and Sarepta plunges
- 6/3 NantHealth leans heavily on Celgene, Soon-Shiong for $91M IPO
- 6/3 MiNA Therapeutics kicks off first-ever PhI saRNA nanoparticle trial
- 6/3 Why does Biogen need a sixth drug for multiple sclerosis?
- 6/3 Unusual combo reduces health risk from atypical antipsychotic
- 6/2 Cancer siRNA player raises cash on route to Phase I
- 6/2 Biogen, Kite Pharma gain EMA hurry-up reviews
- 6/2 Sarepta stock dives on speculation FDA is sidestepping a drug approval
- 6/2 BI launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib
- 6/2 Novartis CEO on Why the Firm Just Opened a Major R&D Facility in China
- 6/2 Two-drug immunotherapy deemed safe for lung cancer patients, Moffitt study shows
- 6/2 Global cancer drug spending to exceed $150 billion by 2020: IMS report
- 6/2 Kite and Cell Design Labs Announce Exclusive Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies
- 6/2 A Look at This Year's ASCO Pipeline
- 6/2 'Collective Wisdom' on Display at ASCO 2016
- 6/1 How can patients get their money's worth from cancer meds? ASCO revamps 'value' tool to help decide
- 6/1 From $4.5 Billion To Nothing: Forbes Revises Estimated Net Worth Of Theranos Founder Elizabeth Holmes
- 6/1 FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors
- 6/1 FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors
- 6/1 Faster CRISPR in mice makes modeling human disease easier
- 6/1 NICE asks Janssen to put ibrutinib forward for the CDF
- 6/1 Genentech, J&J partner AC Immune files IPO for Alzheimer’s pipeline
- 6/1 Curis Announces FDA Acceptance of IND for CA-170, the First Orally Small Molecule to Target and Inhibit Immune Checkpoints
- 6/1 Kite to Highlight Key Data from Engineered CAR T Cell Therapy Pipeline at the 2016 ASCO
- 6/1 Galena Biopharma Receives Fast Track Designation for NeuVax™ (nelipepimut-S) PRESENT Clinical Trial
- 5/31 Why Biotech Stocks Like Alexion May Get Burned
- 5/31 How America Treats Preschoolers With ADHD, In Charts
- 5/31 Done With Apple, Carl Icahn Makes A Bet On Tax-Inverter Allergan
- 5/31 Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)
- 5/31 Interim data encouraging for Regeneron's evinacumab in patients with inherited ultra-high cholesterol
- 5/31 Regeneron Publication in New England Journal of Medicine Links ANGPTL4 Inhibition and Risk of Coronary Artery Disease
- 5/31 Blocked in U.S., Amicus gets a green light for Fabry drug in Europe
- 5/31 4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC 205 in China
- 5/31 Jazz Pharmaceuticals to Buy Celator for $1.5 Billion
- 5/31 Faster, more efficient CRISPR editing in mice
- 5/31 PD-L1 Companion Diagnostics: The Blueprint Project
- 5/27 Valeant turned down Takeda-TPG takeover offer: WSJ
- 5/27 EMA’s CHMP does not recommend approval for Takeda’s Ninlaro for multiple myeloma
- 5/27 FDA approves new diagnostic imaging agent to detect recurrent prostate cancer
- 5/27 FDA approves first buprenorphine implant for treatment of opioid dependence
- 5/27 AstraZeneca’s $2.7B hyperkalemia drug ZS-9 rejected by FDA
- 5/27 AstraZeneca's Fulvestrant Met Its Primary Endpoint as First-Line Treatment in a Phase III Trial for HR+ Advanced Breast Cancer
- 5/27 Surrogate endpoints poor proxy for survival in cancer drug approval process
- 5/27 Roche boosted by early trial success with blood cancer drug
- 5/27 Many Antidepressant Scripts Written for Off-Label Purpose
- 5/27 Approving Sarepta's Muscular Dystrophy Drug Could Force FDA To Get Creative
- 5/27 CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination
- 5/25 Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirinefor Newly Diagnosed AML
- 5/25 Novartis willing to sell Roche stake without demanding premium - CEO
- 5/25 Novartis Highlights Its Strong Foundation For Long-Term, Sustainable Growth At The Third Meet Novartis Management Event
- 5/25 Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- 5/25 US law could increase postdoc pay — and shake up research system
- 5/25 FDA delays decision on whether to approve Sarepta drug for Duchenne
- 5/25 FDA Panel Backs Novo Nordisk Insulin–GLP-1 Combination IDegLira
- 5/25 Eli Lilly Says It Will Launch 20 New Products Through 2023
- 5/25 Our Experience With First-Time Biotech CEOs: Five Behaviors That Matter
- 5/25 Debate over Duchenne drug hits fever pitch as D-day approaches
- 5/25 A new day for 'me-too' meds? EU officials say they're tools for holding prices down
- 5/25 EU lifts suicide warning on Pfizer's smoking-cessation pill
- 5/23 Cancer breakthrough? New 'Universal' T-cell therapy draws praise, doubt
- 5/23 Janssen’s Single-Agent DARZALEX® Approved by European Commission for Treatment of Multiple Myeloma (MM)
- 5/23 H3 Biomedicine to begin trials of first-ever gene-splicing cancer drug
- 5/23 CRISPR simulation upstart taps Celgene, Data Collective for cash
- 5/23 Abemaciclib data highlight Eli Lilly’s case on CDK 4/6
- 5/23 Exelixis Demonstrates Cabozantinib Significantly Improved PFS versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
- 5/23 Drugmakers eye volume growth as China cuts prices by up to 67 percent
- 5/23 Replicating wins? Oncolys licensing bid with Jiangsu centers on oncolytic virus
- 5/23 Novartis: Entresto Gets Class I Recommendation In US,EU Heart Failure Guidelines
- 5/23 Ionis Pharmaceuticals and MD Anderson Form Strategic Alliance to Advance Novel Cancer Therapeutics
- 5/20 The NIH Needs To Increase Efforts To Fight Drug Resistant Bacteria
- 5/20 GSK, AZ hit with deep price cuts in China on key drugs
- 5/20 FDA staffers air concerns over Novo's Victoza-Tresiba combo
- 5/20 Vascepa(R) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels
- 5/20 New immune drugs show long-term survival for deadly cancers
- 5/20 4 behaviors that may cut the risk of cancer by 30 percent
- 5/20 Why a drug that lowers cholesterol doesn’t save lives
- 5/20 Will These Game-Changing Cancer Treatments Hit the Market in 2016?
- 5/20 Novartis launches new Entresto trials in bid to boost sales
- 5/20 New Programming Approach Produces Alloreactive T Cells That Destroy Leukemia Without Added Risk of GvHD
- 5/19 German Merck, Pfizer immunotherapy shows promise in rare skin cancer
- 5/19 Phase III Study of Alecensa® Showed Superior Efficacy Versus Crizotinib in a Specific Type of Lung Cancer
- 5/19 Theranos' Last Defense Crumbles
- 5/19 FDA again delays rule to allow generic drug makers to change labels
- 5/19 Merck, Bristol drugs show longer survival for deadly cancers
- 5/19 Novartis aims to jump-start Entresto with new round of clinical trials
- 5/19 Pfizer cancer drug shows promise in combo with Merck's Keytruda
- 5/19 Horizon to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
- 5/19 Merck's Keytruda shines in pre-ASCO abstract release, with Pfizer catching the limelight, too
- 5/19 Celator Pharmaceuticals® Announces VYXEOS™ Granted Breakthrough Therapy Designation
- 5/18 'Pay For Performance' Drug Plans Could Impact Biopharma's R&D Priorities
- 5/18 FDA Approves Roche Immunotherapy for Bladder Cancer
- 5/18 FDA approves new, targeted treatment for bladder cancer
- 5/18 A tinkerer takes on cancer by hijacking the tiny garbage trucks inside every cell
- 5/18 AstraZeneca set to go head to head against GSK with asthma drug
- 5/18 The mano-a-mano between Pfizer's Ibrance and Novartis' LEE011 nears with early PhIII wrap-up
- 5/18 Novartis breast cancer drug set to take on Pfizer's Ibrance
- 5/18 AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer
- 5/18 AstraZeneca's Lynparza fails in gastric cancer combination test
- 5/18 Pascal Soriot's big experiment: reinventing AstraZeneca
- 5/18 Novartis splits pharma unit as Epstein exits
- 5/17 AbbVie/Roche's Venclexta produces complete remission in 10% of hard-to-treat CLL patients
- 5/17 Nivolumab (Opdivo) for Hodgkin Lymphoma
- 5/17 Pfizer Could Get Its Money’s Worth Out of Anacor Deal
- 5/17 'Cornerstone' patent on AbbVie's Humira comes under PTAB review
- 5/17 South Korea is first to approve next generation lung cancer treatment olmutinib (BI 1482694 / HM61713)
- 5/17 Janssen To Present New Inflammatory Bowel Disease Data At Digestive Disease Week Meeting
- 5/17 Novartis hopes Seretide-topping data can push docs toward Ultibro
- 5/17 Mirror-image enzyme copies looking-glass DNA: Synthetic polymerase is a small step along the way to mirrored life forms
- 5/17 Novartis considers new sales model for experimental cancer therapy
- 5/17 Playing with the big boys – FirstWord discusses the future CDK 4/6 inhibitor market with G1 Therapeutics CEO Mark Velleca
- 5/17 AstraZeneca asthma drug hits goal, to enter competitive market
- 5/16 Beyond immuno-oncology, AstraZeneca builds up 'DNA damage' drugs
- 5/16 BioIntegrator Announces the Second Market Registration of Nescler, a First Generic of the Novartis MS Blockbuster Gilenya
- 5/16 Curing Cancer Through a Better Business Model
- 5/16 Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel
- 5/16 Aduro Biotech Announces Phase 2b ECLIPSE Trial Misses Primary Endpoint in Heavily Pretreated Metastatic Pancreatic Cancer
- 5/16 Penn, Biogen Launch $2B Gene Therapy Alliance
- 5/16 FDA Approves Lenvatinib/Everolimus for Advanced RCC
- 5/16 The Remarkable Rebirth of Cancer Immunotherapy
- 5/16 Vermont backs bill for increased drug pricing transparency
- 5/16 Valeant ups drug discounts, but congressional critic isn't impressed
- 4/29 Amgen profit sails past Street expectations; raises 2016 outlook
- 4/29 Big Enbrel beat, lower expenses help Amgen top Q1 forecasts
- 4/29 Galapagos, AbbVie Expand CF Collaboration to Up-to-$600M
- 4/29 FDA approves first generic Crestor
- 4/29 Novel therapy programs the death of cancer cells
- 4/29 Sanofi Profit Little Changed as Drugmaker Pursues Medivation
- 4/29 Medivation's Board of Directors Unanimously Rejects Sanofi's Unsolicited Proposal
- 4/29 How Medivation Rose From Penny Stock to $9.3 Billion Deal Target
- 4/29 Gilead’s Profit, Hepatitis C Drugs Sales Miss Estimates
- 4/29 AstraZeneca cuts costs and doubles down on cancer drugs
- 4/28 This CEO's $148 Million in Pay May Rank Him No. 1 for 2015
- 4/28 Sanofi launches $9.3 blillion fight for U.S. cancer firm Medivation
- 4/28 CRISPR/Cas9 pioneer Intellia outlines its plans for $140M IPO
- 4/28 FDA Grants Advaxis Fast Track for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
- 4/28 AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion
- 4/28 AbbVie to Acquire Cancer Drugmaker Stemcentrx for $5.8 Billion
- 4/28 Exclusive: The Woman Behind the 'Female Viagra' Has a New Venture
- 4/28 Pfizer to Pay $784.6 Million to Resolve Drug Discount Case
- 4/28 AbbVie Reports First-Quarter 2016 Financial Results
- 4/28 GlaxoSmithKline's Q1 sales rise 11 percent, driven by growth of new drugs
- 4/27 What will next-gen cancer cocktails cost? It's all about value, execs say
- 4/27 Retroviral DNA Findings May Lead to Better Therapies for HIV Infection
- 4/27 Adimab Launches Kodiak Collaboration, Gains Licenses from Lilly, Kite, and Jounce
- 4/27 Valeant may have a new chief executive, but its future remains dim
- 4/27 Patients with Advanced Metastatic Colorectal Cancer in Europe Now Have a New Treatment Option as LONSURF®Receives EU Approval
- 4/27 Oasmia Announces Positive Overall Survival Results from Phase III Study of Paclical/Apealea for Treatment of Ovarian Cancer
- 4/27 Bioinformatics: Breaking the bottleneck for cancer research
- 4/27 The 20 fastest growing pharmaceutical brands
- 4/27 Biogen Appoints Michael Ehlers Executive Vice President, Research and Development
- 4/27 Pharmacists Can Manage Some Chronic Conditions Effectively, Study Suggests
- 4/19 Windfall for cancer research sets off a scramble for clout
- 4/19 FDA pulls approvals on AbbVie's ex-blockbuster heart meds
- 4/19 Enhanced Systemic Anti-Tumor Activity from Combination Treatment with Intra-tumoral IMO-2125 and IDO-1 Inhibitor
- 4/19 Shire seeks FDA approval for chewable version of ADHD drug Vyvanse
- 4/19 Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1
- 4/19 Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors
- 4/19 What A Toddler And Her Tumor Can Teach Us About Cancer Research
- 4/19 Innate Pharma presents new CD73 checkpoint inhibitor program
- 4/19 AACR 2016: CRISPR as a Screening Tool for Drug Targets
- 4/19 Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib)
- 4/19 ‘Manhattan Project’ for cancer aims to turn it into a chronic illness, not a death sentence
- 4/18 AstraZeneca Presents DNA Damage Response Science at the AACR 2016 Annual Meeting
- 4/18 CD4 T-cell immunotherapy that targets MAGE-A3 shows promise in metastatic cancer
- 4/18 J&J's Invokana under scrutiny in EU for potential link to toe amputations
- 4/18 Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL
- 4/18 Enumeral, Pieris enter license, transfer agreement for anti-PD-1 antibody program ENUM 388D4
- 4/18 BMS' Opdivo produces 5-year survival rate for a third of advanced melanoma patients
- 4/18 AstraZeneca eyes Xtandi windfall with potential £7B bid for Medivation
- 4/18 AstraZeneca has held internal talks for Medivation bid: Sunday Times
- 4/18 Gene-Editing Technique Improves Immunotherapy
- 4/18 Merck Receives BTD from U.S. FDA for KEYTRUDA® in Classical Hodgkin Lymphoma (cHL)
- 4/13 Pfizer to lean on vaccines following Allergan deal bust, report says
- 4/13 Chinese Scientists Defy Ethics, Double Down on Editing Human Embryos
- 4/13 ‘Breakthrough’ can be an effective marketing term for some drugs
- 4/13 PDS Biotechnology Reports Positive Phase 1 Study Results for PDS0101 Immunotherapy for HPV-Related Cancers
- 4/13 Boehringer's Giotrif beats AZ' Iressa in lung cancer trial
- 4/13 FDA Accepts sBLA for KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
- 4/13 With $250M Grant, Sean Parker Launches Cancer Immunotherapy Institute
- 4/13 FDA Allows First Switch From Batch to Continuous Manufacturing for HIV Drug
- 4/13 Medivation Said to Have Rebuffed Sanofi Takeover Approach
- 4/13 Tackling the financial toll of cancer, one patient at a time
- 4/11 How Best To Address The Increase In Liver Cancer Deaths
- 4/11 FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality
- 4/11 Viking Therapeutics Presents Positive Phase 1b Clinical Data on VK2809 in Hypercholesterolemic Subjects
- 4/11 Regeneron, Intellia Partner to Develop CRISPR/Cas Therapeutics
- 4/11 Roche's atezo steps on FDA fast track, speeding up lung cancer showdown with Opdivo, Keytruda
- 4/11 ARIAD Announces Initiation of First-Line Phase 3 Trial of Brigatinib in Treatment of ALK-Positive NSCLC
- 4/11 AstraZeneca, Eli Lilly in Final Stage of Testing Alzheimer’s Drug
- 4/11 Lilly scientists look to space to help research
- 4/11 Ensituximab Shows Promise in Refractory mCRC
- 4/11 Celgene Exercised Option to Develop and Commercialize Juno's CD19-directed Product Candidates
- 4/8 Outside Experts Hired By Theranos See Promise But Still Seek Proof
- 4/8 FDA takes steps to withdraw approval of the swine drug carbadox due to safety concerns
- 4/8 Asthma inhalers celebrate 60th anniversary with debate on over-prescription
- 4/8 Hitting HIV with CRISPR/Cas9 Can Arouse Resistance
- 4/8 Immunotherapy Combinations Coming to the Forefront in Melanoma
- 4/8 FDA reviewers question efficacy, raise safety issues and cite a challenge on Clovis' rociletinib
- 4/8 Eating fresh fruits daily may reduce your risk of cardiovascular death
- 4/8 Scientists identify possible double whammy to attack leukaemia
- 4/8 FDA approves Abiomed's device to treat cardiac shocks
- 4/8 Treatments Suppress Immune Response and May Promote Relapse
- 4/7 Juno Therapeutics (JUNO), WuXi AppTec Form Joint Venture in China
- 4/7 Michael A. Caligiuri, MD, Named American Association for Cancer Research President-Elect 2016-2017
- 4/7 Allergan takes Linzess on a run with differentiation push
- 4/7 Shire promises Treasury rules won't nix its deal for U.S.-based Baxalta
- 4/7 US panel backs Intercept's Ocaliva for primary biliary cholangitis
- 4/7 Allergan Joins Heptares in $3.3B+ Neurological Drug Alliance
- 4/7 Docs won’t prescribe pricey new cholesterol meds unless they lower heart risks
- 4/7 FDA Accepted of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer
- 4/7 Ancient Algae Offer New Hope for Hard-to-Treat Cancers
- 4/7 Allergan Boss Brent Saunders On The Failed Pfizer Deal And Why He's Not Like Valeant
- 4/6 Facing a new assessment of Kyprolis, Amgen castigates cost-effectiveness team's methods
- 4/6 FDA approves first leadless pacemaker to treat heart rhythm disorders
- 4/6 Are Red Wine, the Microbiome, and Heart Disease Molecularly Linked?
- 4/6 Nanogel that delivers one-two punch to cancer heads to clinical trial
- 4/6 AstraZeneca and Takeda DPP-4 inhibitors get another warning added to their labels
- 4/6 Ludwig Cancer Research and the Cancer Research Institute Initiate Clinical Trial of a Novel Combination Immunotherapy for Ovarian Cancer
- 4/6 Tesaro Rises on $85 Million J&J Cancer Drug Licensing Deal
- 4/6 Merck CEO Ken Frazier Is Looking Smart For Avoiding A Tax Inversion
- 4/6 Pfizer and Allergan Call Off Merger After Tax-Rule Changes
- 4/6 What do gamblers and doctors have in common?
- 4/6 Insulin cost in U.S. more than doubles between 2002-2013
- 4/5 Pfizer Vs. Obama: The Treasury Tries To Stop Pharma's Tax Dodge
- 4/5 Biogen, Samsung accuse AbbVie of evergreening Humira patents to block biosims
- 4/5 FDA approves Inflectra, a biosimilar to Remicade
- 4/5 MedImmune, Regeneron Launch Cancer Collaboration
- 4/5 Insulin prices have skyrocketed, putting drug makers on the defensive
- 4/5 Merck KGaA and Pfizer Announce First Patient Treated in Phase III Combination with Avelumab and INLYTA® in Renal Cell Carcinoma
- 4/5 CytRx Corporation (NASDAQ:CYTR) Surges as Aldoxorubicin Phase 3 Trial Achieves Event Targets
- 4/5 Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.
- 4/5 Allergan Could Buy These Drug Companies if the Pfizer Merger Is Scuttled
- 4/5 Pfizer Vs. Obama: The Treasury Tries To Stop Pharma's Tax Dodge
- 4/5 FDA clears novel HIV therapy Descovy
- 4/5 Sorrento Announces Definitive Agreements for up to $150 Million Private Placement
- 4/4 ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data
- 4/4 FDA proposes biosimilar labeling that favors generic drug makers
- 4/4 Did Clovis play a deceptive game with rociletinib data in leadup to its PhIII stunner?
- 4/4 Oxford BioTherapeutics Licenses Nerviano Medical Sciences' Drug-Linker Technology to Develop Novel Antibody Drug Conjugates
- 4/4 New cholesterol methods needed in wake of failed drugs, heart researchers say
- 4/4 Regeneron's Skin-Clearing Drug Hits Goals in Late Trials
- 4/4 Gilead Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases
- 4/4 Some People Really Can't Take Statins For High Cholesterol, Scientists Prove
- 4/4 Cholesterol-lowering statins cut heart disease risk in people with slightly high blood pressure
- 4/4 NYU Tandon researcher synthesizes hybrid molecule that delivers a blow to malignant cells
- 3/31 Will SCOTUS take up Sandoz' pivotal biosim case? New briefs call on court to weigh in
- 3/31 U.K. industry lobby group to write pro-pharma features with newspaper that berates it
- 3/31 Asahi Kasei Pharma to Co-Develop Array BioPharma's Pain Candidates
- 3/31 Dr. Reddy's Buys Ex-Asia Rights to Eisai Cancer Candidate E7777
- 3/31 Pfizer-Allergan Deal Faces In-Depth Antitrust Probe by U.S.
- 3/31 The Spike in Drug Costs: Rheumatoid Arthritis
- 3/31 EMA Validates Bristol-Myers Squibb’s Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients
- 3/31 Daratumumab Triplet Delays Progression in Multiple Myeloma
- 3/31 GlaxoSmithKline Reaffirms Its Commitment To Oncology Research But The Strategy Is Unclear
- 3/31 Chinese Market Offers New Life to Many Drugs
- 3/30 Two-stage nanoparticle smart bomb targets lung, breast cancer cells
- 3/30 FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow
- 3/30 Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways
- 3/30 Curing Cancer Is Within Reach
- 3/30 GlaxoSmithKline Reaffirms Its Commitment To Oncology Research But The Strategy Is Unclear
- 3/30 FDA Review Times Steadily Decreasing, Report Finds
- 3/30 Gene targeting reverses cardiac fibrosis in heart-failure models
- 3/30 Lundbeck Slumps After FDA Rejects Brintellix Label Expansion
- 3/30 Drugmakers move to counteract expiring patents with new respiratory drugs
- 3/30 FDA panel backs Acadia drug for psychosis linked to Parkinson's
- 3/29 Sanofi Names Yong-Jun Liu Head Of Research, Global R&D, Effective April 1
- 3/29 In surprise decision, FDA blocks crucial cognitive claim for Takeda's Brintellix
- 3/29 Tesaro, MD Anderson Launch Immuno-Oncology Collaboration
- 3/29 What Valeant’s fall from grace can teach the drug industry
- 3/29 Biosimilar drugs could save up to $110 billion by 2020: IMS
- 3/29 Puma Biotechnology updates NDA Filing Anticipated Mid-2016 for neratinib
- 3/29 Galena Biopharma Phase 3 PRESENT Clinical Trial with NeuVax™ (nelipepimut-S) Achieves 70th Qualifying Disease Free Survival Event
- 3/29 Valeant's Sprout Problem
- 3/29 T-DM1 Now Standard for Heavily Pretreated HER2+ Breast Cancer
- 3/29 Seattle Genetics' ambitious plan for 12 more drugs, 100 more employees
- 3/28 Dr. Reddy's Acquires U.S. Rights to XenoPort's Phase III Psoriasis Candidate
- 3/28 Aduro, UC Berkeley Establish Immunotherapy Alliance
- 3/28 Expert Projects 2016 FDA Approvals of Nivolumab and Pembrolizumab in Head and Neck Cancer
- 3/28 Glenmark gets two ANDA approvals from USFDA
- 3/28 Breast Cancer Resistance to CDK4/6 Inhibitors Arises in Many Ways
- 3/28 Lion Biotechnologies Names Michael T. Lotze Chief Scientific Officer
- 3/28 Gilead to Pay Merck $200 Million in Damages Over Hepatitis C Drug Patents
- 3/28 With two PhIII schizophrenia trials in ruins and Alzheimer's on hold, Forum chops staff and considers options
- 3/28 Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma
- 3/28 Prescription Drug Prices Have Doubled in Just 7 Years for Older Americans, Study Shows
- 3/28 Chinese authorities arrest more than 130 people in relation to vaccine scandal
- 3/28 FDA staff says Acadia's drug for Parkinson's disease psychosis is effective
- 3/25 7 New Blockbuster Drugs to Watch in 2016
- 3/25 Forum Pharmaceuticals to Restructure after Phase III Failures
- 3/25 Pharmalot, Pharmalittle: Gilead ordered to pay $200m to Merck in patent row
- 3/25 OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors
- 3/25 Alirocumab (Praluent) Succeeds in Cholesterol Study
- 3/25 U.S FDA issues draft guidance for abuse-deterrent opioid generics
- 3/25 How Allergan Rose and Valeant Fell
- 3/25 Imperial scientists find a key miRNA that silences breast and lung cancers in the lab
- 3/25 WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia
- 3/25 With Andrew Witty's Departure, Will GlaxoSmithKline Say Goodbye to Fraud?
- 3/24 Craig Venter Just Hacked Bacteria To Have The Smallest Genome Possible
- 3/24 Novartis wraps up China bribery probe with $25M payment to SEC
- 3/24 FDA takes important step to increase the development of, and access to, abuse-deterrent opioids
- 3/24 Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer
- 3/24 Lenalidomide Significantly Boosts PFS in Mantle Cell Lymphoma
- 3/24 I-O allure boosts Corvus Pharmaceuticals through $70.5M IPO on Nasdaq
- 3/24 Dying has become more expensive for some thanks to a Valeant price hike
- 3/24 Orphan Drugs More Innovative Than Non-Orphan Products
- 3/24 Ally Bridge keeps cash flowing in $155M private placement in Tesaro
- 3/24 Biotech Roars Back On Forbes' List Of The Top Venture Capitalists
- 3/24 Sanofi, Regeneron's PCSK9 inhibitor Praluent meets primary endpoint of late-stage trial
- 3/23 FDA approves Cinqair to treat severe asthma
- 3/23 Why one analyst thinks a Sanofi and Regeneron cholesterol drug will be yanked
- 3/23 Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy
- 3/23 Innovative Russian Medicine Mobilizes Human Immune System to Fight Cancer
- 3/23 Sunesis Announces First Subject Dosed in Phase 1A Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062
- 3/23 Brazil's controversial cancer pill fares poorly in tests
- 3/23 Argos Therapeutics Announces a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer
- 3/23 BMS to Acquire Padlock Therapeutics for Up to $600M
- 3/23 AstraZeneca's Brilinta/Brilique Fails Phase III Trial in Stroke Patients
- 3/23 ASCO Tool Found to be an Effective and Easy Way to Manage and Monitor Clinical Trial-Associated Workload
- 3/23 Cohesin Ring Rules Blood Stem Cells, Binds Them to Renewal or Expansion
- 3/23 OncoQuest Signs Agreement with Shenzhen Hepalink to Fund Immunotherapy for Treatment of Cancer in China
- 3/23 Apple launches CareKit to help people manage their medical conditions
- 3/23 Merck Wins Chance for Royalties on Gilead’s Hepatitis C Cure
- 3/22 What GlaxoSmithKline CEO Andrew Witty Doesn't Get About Drug Pricing
- 3/22 Amgen's PCSK9 patent win 'reasonably likely' to push Sanofi's Praluent off the market: Analyst
- 3/22 FDA approves new psoriasis drug Taltz
- 3/22 India denies plans to restrict compulsory licenses for drugs
- 3/22 Nanoparticle-based cancer therapies shown to work in humans
- 3/22 Immunotherapy a Mainstay in Kidney Cancer, Novel Approaches on Horizon
- 3/22 RNA May Surpass DNA in Precision Medicine
- 3/22 Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial
- 3/22 FDA urged to approve Sarepta DMD drug by dozens of medical experts
- 3/22 Moberg Pharma Announces Plans to Develop BUPI Through Phase III
- 3/22 China’s diabetes boom promises $23 billion pot for drug makers
- 3/22 BRIEF-Oncolytics says ovarian cancer drug shows benefit in mid-stage study
- 3/21 J&J, BMS are delivering solid sales from new meds. The rest of Big Pharma, not so much: Forbes
- 3/21 FDA approves new treatment for inhalation anthrax
- 3/21 Is It Time To Go Bargain Hunting In Valeant Pharmaceuticals Stock?
- 3/21 You'll Never Guess Which Pharma Likely Owns 40% of 2016's New Blockbusters
- 3/21 Onconova Enrolls First Patient for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes
- 3/21 Chi-Med Initiates Sulfatinib Phase III Registration Study in Pancreatic Neuroendocrine Tumor Patients
- 3/21 Cerulean Presents CRLX301 Phase 1 Data at the 14th International Congress on Targeted Anticancer Therapies
- 3/21 Pictilisib Enhances Suppression of Tumor Cell Proliferation in Breast Cancer
- 3/21 Pfizer presents detailed Phase III findings for JAK inhibitor tofacitinib in ulcerative colitis
- 3/21 Tech Megatransfer: Merck Pays Harvard $20M For “Accelerated” Cancer Drugs
- 3/21 A New Look At The Most Innovative Pharma Companies (And Whether They Are Sustainable) -- Part I
- 3/18 Amgen triumphs in PCSK9 patent litigation – five key questions
- 3/18 Gilead's oncology chief left ahead of company halting Zydelig trials
- 3/18 Senators lambaste Turing for 'unethical' price hikes at latest drug price hearing
- 3/18 Unisex Contraception One Step Closer to Reality
- 3/18 Germany's Bayer wins U.S. FDA approval for hemophilia A therapy
- 3/18 Clinical development of modern cancer drugs get a boost from a forgotten drug candidate
- 3/18 BRIEF-Celsion says phase 1/2 combination trial is expected to begin in mid-2016 for gen-1 il-12 immunotherapy
- 3/18 Doctors taking a shine to biosimilars as they get experience with them
- 3/18 Ramucirumab Does Not Prolong Corrected QT Interval
- 3/18 BerGenBio Secures NOK212 Million Capital Raise
- 3/17 Five Lessons Big Pharma Should Learn From Valeant's Collapse
- 3/17 Antidepressants tied to lower dementia mortality
- 3/17 J&J chief Gorsky suffers cuts in bonus, incentive pay, but still racks up $23.8M
- 3/17 Amgen Bests Regeneron in Patent Fight Over Cholesterol Drugs
- 3/17 Allergan Confirms Generic Abraxane® Patent Challenge
- 3/17 FDA Proposes New Databases to Monitor CAR T-Cell Safety Across INDs
- 3/17 Identification of a novel tyrosine kinase inhibitor for acute myeloid leukemia
- 3/17 Trial Surprise: Rigosertib May Benefit Some MDS Patients
- 3/17 GlaxoSmithKline CEO Andrew Witty to Retire in March 2017
- 3/17 Easy navigation beats out trustworthiness for health info, survey finds
- 3/16 Novartis-allied scientist at Penn creates a new CAR-T model for solid tumors
- 3/16 Horizon CEO Walbert scores $93M--yes, $93M--in 2015 compensation
- 3/16 NSF Funds NanoHybrids’ Improved Chemotherapy Delivery Platform
- 3/16 Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine
- 3/16 Amgen prevails in high-stakes PCSK9 patent fight with Sanofi, Regeneron
- 3/16 Why some tumors withstand treatment
- 3/16 Roche Partners with Blueprint Medicine on Cancer Immunotherapy
- 3/16 After $600 Million Typo, Valeant CEO Is Back on the Hot Seat
- 3/16 Sanofi signs deal worth up to $2.3 billion with DiCE Molecules
- 3/16 New Lung Cancer Therapy May Target Previously Untreatable Tumors
- 3/16 Heart Failure Drug Could Treat Herpes Virus, Suggests Study
- 3/15 Orexigen Re-Acquires U.S. Rights to Contrave from Takeda
- 3/15 FDA changes policy to prevent the next Martin Shkreli
- 3/15 FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection
- 3/15 There’s a new theory about why some cancer therapies fail. It’s about timing
- 3/15 New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows
- 3/15 T-Cell Pioneer Carl June Acknowledges Key Ingredient Wasn’t His
- 3/15 New drug hope for mesothelioma
- 3/15 Celator Announces Phase 3 Trial for VYXEOS™ (CPX-351) in Patients with AML
- 3/15 Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic Cancer
- 3/15 HUYA Bioscience International Acquires Exclusive Rights to Immuno-Oncology Products from Fudan University
- 3/15 Five Companies Face Big FDA Decisions This Month
- 3/11 Could Viagra increase the risk of skin cancer? Erectile dysfunction drug 'stimulates the growth of melanoma'
- 3/11 EMA puts Gilead's Zydelig under the lens after deaths crop up in trials
- 3/11 Too Much Good Cholesterol May Be a Bad Thing
- 3/11 ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas
- 3/11 Pancreatic Cancer Vaccine Makes Progress in Two Late-Stage Trials
- 3/11 FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer
- 3/11 Widely used kidney cancer drugs can't stop recurrence
- 3/11 VA to stop restricting hep C drugs, offering them to all infected veterans
- 3/11 EU revokes one of the patents on Biogen blockbuster Tecfidera
- 3/11 Breast cancer study finds 'astonishing' drug combination that gives results
- 3/10 Targovax announces encouraging interim results with RAS specific peptide vaccine in resected pancreatic cancer
- 3/10 AbbVie chief secures his spot on biopharma's highest-paid list with $20M in 2015 compensation
- 3/10 Vericel Corp's heart drug meets main goal in mid-stage study
- 3/10 6 Ways Pharma May Use Social Media
- 3/10 US prescription drug spending increases to an estimated $457 billion in 2015
- 3/10 What’s in a biotech name? How drug startups choose their brand
- 3/10 Price pressures suppressing pharmaceutical growth in China: report
- 3/10 How the US CRISPR patent probe will play out
- 3/10 CRISPR everywhere
- 3/10 What Ted Cruz Gets Wrong About The FDA: Tough Regulation Can Spark Innovation
- 3/9 Why Is No One Buying 'Pink Viagra'?
- 3/9 What Ted Cruz Gets Wrong About The FDA: Tough Regulation Can Spark Innovation
- 3/9 Surprise proposal: Medicare wants to jump on the value-based pricing bandwagon
- 3/9 Bristol-Myers scraps doc payments in China after last fall's FCPA settlement
- 3/9 Nanoparticles Reveal Membrane Proteins' Structure and Function
- 3/9 Inhaled Salmeterol + Fluticasone Propionate Better Than Fluticasone Propionate Alone in Reducing Asthma Exacerbations
- 3/9 U.S. FDA to allow Amarin to promote fish oil pill for off-label use
- 3/9 Zarxio one year on: US biosimilars market still riddled with uncertainty, expert
- 3/9 Nivolumab, Pembrolizumab Compete for Top Choice in NSCLC Treatment
- 3/9 Cantargia AB’s CAN04 product candidate shows good safety after repeated doses in new toxicity study
- 3/9 U.S. FDA Lifts Partial Clinical Hold on Medivation's Pidilizumab
- 3/9 How Novo Nordisk Makes Money
- 3/8 Three new drugs cleared for use on NHS Scotland
- 3/8 Soricimed Granted Orphan-Drug Designation from the U.S. FDA for Treatment of Ovarian Cancer
- 3/8 Former FDA Official Calls For Tougher Restrictions On Obesity Drug Contrave
- 3/8 With $70M in VC cash, Tizona takes a fresh approach to immuno-oncology
- 3/8 Illumina CEO Jay Flatley Built The DNA Sequencing Market. Now He's Stepping Down
- 3/8 Sanofi, Merck to split up their long-standing vaccines JV in Europe
- 3/8 After bribery episode, Bristol-Myers ends ‘certain initiatives’ in China
- 3/8 Gilead, Merck Spar Over Hepatitis C $1,000-Pill Royalties
- 3/8 Heat Biologics Presents Positive ComPACT Preclinical Data at the Keystone Symposia
- 3/8 New therapeutic target in myeloma discovered
- 3/7 Five Ways Innovation Is Advancing Public Health
- 3/7 AbbVie, Boehringer Ingelheim Launch $595M+ Collaboration to Develop Phase III Psoriasis Candidate
- 3/7 15 Top-Selling Drugs Launched in 2015
- 3/7 3SBio's PEG-irinotecan Wins IND Approval From China FDA
- 3/7 FDA Accepts sBLA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
- 3/7 FDA clears Imbruvica as chemo alternative for first-line CLL
- 3/7 VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy
- 3/7 BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111
- 3/7 BRIEF-Glaxosmithkline says presents new data on efficacy of Nucala
- 3/7 Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor
- 3/7 Drugmakers exploit REMS to restrict generics, and it doesn't bode well for biosimilars
- 3/7 Celldex Brain Cancer Vaccine Disappoints, Phase III Trial To Be Discontinued
- 3/4 U.S. FDA Approves IMBRUVICA® (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia
- 3/4 Survey: Half of U.S. docs expect to prescribe more biosims in the next three years
- 3/4 FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B
- 3/4 Could Twitter Be a Recruitment Tool for Cancer Trials?
- 3/4 UCLA will get hundreds of millions for rights to prostate cancer drug
- 3/4 Open Spigot on Novartis' Pipeline
- 3/4 GSK Names Winners of 2015 Discovery Fast Track Challenge
- 3/4 Horizon, Centauri Form Immuno-Oncology Joint Venture
- 3/4 This $150,000 Cancer Treatment Saved a Pharma Company
- 3/4 Merck launches late-stage trials for Humira biosimilar
- 3/3 Are Drug Companies Reaping Extra Profits By Selling Oversized Doses Of Cancer Drugs?
- 3/3 Trump's healthcare plan backs drug reimportation, but leaves out Medicare price negotiation
- 3/3 FDA wants to nix voucher program for rare pediatric disease drugs
- 3/3 BUZZ-India's Dr Reddy's rises on FDA approval for anti-nausea drug
- 3/3 Juno, Kite race to the FDA finish line with breakthrough CAR-T drugs
- 3/3 Drug combination slows breast cancer spread
- 3/3 Sanofi Genzyme enlists Hollywood star to help sell MS drugs
- 3/3 FDA Approves New Indication for FASLODEX® (fulvestrant)
- 3/3 Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
- 3/3 Clinigen Expands into U.S. with Totect Acquisition
- 3/3 Stealthy MIT Spinout Ribon, Led by a Sanofi Vet, Takes Aim at Cancer
- 3/2 Genetically Engineered Killer T-Cells That Seek Out Brain Tumors Read more from Asian Scientist Magazine
- 3/2 Chi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer
- 3/2 U.K. cost watchdogs snub key J&J med Imbruvica on first go-around
- 3/2 Pharmalot, Pharmalittle: Drug makers accused of misleading medical journal on blood thinner
- 3/2 New Haven Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control
- 3/2 Roche chalks up second approval for Gazyva
- 3/2 The Opioid Treatment Business Is Booming
- 3/2 Pharma goes to court in Ohio to stop drug pricing ballot initiative
- 3/2 Mylan's EpiPen Boosted as FDA Sees Holes in Teva Application
- 3/2 FDA wants to know whether animated ads distort drug risks
- 3/2 Glucose In, Heart Disease Out
- 3/1 FDA Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® for the Treatment of HIV-1 Infection
- 3/1 FDA swats down Teva's EpiPen copy, putting Mylan in cruise control
- 3/1 In the trash: Wasted cancer drugs cost nearly $3 billion each year
- 3/1 Analysis questions benefit of female libido drug
- 3/1 Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says
- 3/1 Valeant Says It's Under Investigation by SEC, Shares Plunge
- 3/1 Trevena Gets FDA Breakthrough Therapy Designation for Oliceridine
- 3/1 His Job Is to Sell a $1,000 Pill for $10 Without Losing Money
- 3/1 Adding Immunotherapy to RFA May Benefit Colorectal Cancer Patients With Liver Metastasis
- 3/1 Can PhRMA's New Boss Help Change The Industry's Image?
- 3/1 Five Reasons To Be Optimistic About The Precision Medicine Initiative
- 3/1 Tremelimumab Misses OS Endpoint in Phase IIb Mesothelioma Trial
- 2/29 SELLAS Announces FDA Orphan Drug Designation for WT1 Cancer Vaccine in Patients with Malignant Pleural Mesothelioma
- 2/29 FDA needs more time (again) to review Heron's SUSTOL NDA, new action date to be announced later this week
- 2/29 Genentech bags US nod for Gazyvaro in follicular lymphoma
- 2/29 Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program
- 2/29 Sanofi, University of Tokyo partner for drug discovery
- 2/29 Protalex Receives Positive Interim Review in Its U.S. Phase 1/2 Study of PRTX-100 for Immune Thrombocytopenia
- 2/29 Boehringer, AbbVie Said to Be in Cancer-Partnership Talks
- 2/29 Potential Treatment for Huntington's Disease, Found Effective, Safe in Mice, Monkeys, Enters Clinical Testing
- 2/29 Rivals chase Bristol-Myers in cancer immunotherapy drug race
- 2/26 Top 25 orphan drugs, by 2015 global sales
- 2/26 China says to speed up approvals for some drugs
- 2/26 Lilly moves toward psoriasis showdown with Novartis in EU
- 2/26 Opdivo wins thumbs up from CHMP for two indications, in lung and kidney cancers
- 2/26 A billion-dollar patent fight over gene editing hits the courts
- 2/26 U.S. reps push for Pfizer penalties on report that it's dodging $35B in U.S. taxes
- 2/26 Report: Pfizer dodging $35B in taxes
- 2/26 AstraZeneca's $4 billion Acerta deal endorsed by orphan drug status
- 2/26 Duchenne Race May Have No Winner
- 2/26 Deadly French trial drug had already proved fatal on dogs
- 2/26 Baxalta, Precision BioSciences enter deal potentially worth up to $1.7 billion to develop CAR T-cell therapies
- 2/26 Obama administration moving ahead with major project to match treatments to people's genes
- 2/25 Obama Is Using The Bully Pulpit To Set Patient Data Free
- 2/25 How to bring down generic drug costs? Tweak the FDA's approval rules, health experts say
- 2/25 Vanderbilt, Google's Verily to Launch Precision Medicine Initiative Cohort
- 2/25 4-Factor Prothrombin Complex Concentrate (PCC) Superior to 3-Factor PCC in Reversing Warfarin-Induced Bleeding
- 2/25 Seattle Genetics Initiates Phase 1 Trial of SGN-CD19B for Patients with B-cell Non-Hodgkin Lymphoma
- 2/25 Johnson & Johnson tops IDEA Pharma’s Productive Innovation Index for the fourth consecutive year
- 2/25 Google backs $75M A round for Stanford's immuno-oncology spinout Forty Seven
- 2/25 Lilly wins European approval for lung cancer drug Portrazza
- 2/25 Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets
- 2/25 Addressing Generic Drug Unaffordability And Shortages By Globalizing The Market For Old Drugs
- 2/24 FDA Gets New Leader as Senate Confirms Nominee Califf
- 2/24 EU green light for Lilly's lung cancer drug Portrazza
- 2/24 Regen BioPharma, Inc. Completes Preclinical Experimentation for Its siRNA NR2F6 Checkpoint Inhibitor
- 2/24 Protein engineering program at Ohio State modulates heart contraction in mice
- 2/24 Bayer sees new med Kovaltry as just one piece of its hemophilia puzzle
- 2/24 CAR trials drive leukemia and lymphoma treatment in new direction
- 2/24 Juno scientific co-founder Stan Riddell adds another upgrade to CAR-T
- 2/24 Juno, Fred Hutch Launch Clinical Trials Unit
- 2/24 FDA rejects application for Duchenne drug, rattling investors and parents
- 2/24 Does NASH need a Big Pharma dash?
- 2/24 Will Merck Encroach On Gilead's Harvoni Territory?
- 2/24 CFDA releases the list of 2015 approved drugs
- 2/24 Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes
- 2/23 Prescription Drug Cost Growth May Be Slowing, CVS Says
- 2/23 10 Breakthrough Technologies 2016
- 2/23 Myriad Genetics expands CDx strategic research collaboration with AbbVie to support development of veliparib
- 2/23 Ignyta Ends Development of Three Cancer Candidates
- 2/23 Amgen to Develop Unilife Injectable Drug Delivery Systems
- 2/23 The biosimilar ploy that could save billions in health care costs
- 2/23 Sanofi Redeems $245M Priority Review Voucher for Type 2 Diabetes Treatment
- 2/23 Ibuprofen patch heralds side effect free drug future
- 2/23 The top 20 drugs in 2020--worldwide sales
- 2/23 Did Amgen, UCB’s Phase III trial design for romosozumab backfire?
- 2/23 Crafting a better T cell for immunotherapy
- 2/23 Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study
- 2/22 Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer
- 2/22 OBI Pharma Reports Topline Results of OBI-822/821 Phase 2/3 Clinical Trial In Patients With Metastatic Breast Cancer
- 2/22 Merck CEO Frazier: Pharma needs to justify price hikes
- 2/22 How should FDA revamp its off-label marketing rules? An expert panel backs big changes
- 2/22 MannKind Founder Alfred E. Mann Resigns as Executive Chairman
- 2/22 Michael Jaharis, Billionaire Pharmaceutical Leader, Dies at 87
- 2/22 Alexion Tests Orphan Drug Limits
- 2/22 Former sales rep for painkiller company pleads guilty
- 2/22 Mylan joins the Advair-copycat queue, but approval could be a long slog
- 2/22 Mylan's ANDA for Generic Advair Diskus® Accepted for Filing by FDA
- 2/19 AstraZeneca bags EU approval for gout drug Zurampic as it eyes $500M in sales
- 2/19 FDA approves Briviact to treat partial onset seizures
- 2/19 Overdose deaths from common sedatives have surged, new study finds
- 2/19 FDA Allows Banned Chinese Firm to Ship Chemotherapy to US as Shortage Threat Looms
- 2/19 Intensive Diabetes Therapy Cuts CVD Incidence by 30 Percent
- 2/19 Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for EOquin® (apaziquone for intravesical instillation)
- 2/19 Engineering nanoparticles that can change their shape to deliver cancer drugs to tumours
- 2/19 Blinatumomab Nears 70% Response Rate in Non-Hodgkin Lymphoma
- 2/19 Prostate cancer treated more aggressively in the city
- 2/19 Novartis' precision leukaemia drug gets breakthrough status
- 2/18 NEJM study finds Actos holds off repeat strokes, heart attacks in insulin-resistant patients
- 2/18 New results from low-T trial point to early win for AbbVie's AndroGel
- 2/18 Canadian provinces close the door on Alexion over price of rare disease drug
- 2/18 Regulus Bolsters Argument for Effective Hepatitis C Injection
- 2/18 AstraZeneca wins FDA breakthrough status for key cancer drug
- 2/18 Prescription drug spending spikes 12 percent, reaching nearly $300 billion
- 2/18 Apatinib Shines in Gastric Cancer Trial
- 2/18 Caribou Bio’s New CRISPR Patent Isn’t About Gene Editing
- 2/18 Astellas: Ten years young
- 2/18 Opening The Book On Pharma Won't Impact Drug Costs -- Nor Should It
- 2/18 Using CRISPR/Cas9, UCLA team corrects Duchenne mutation in human cells
- 2/18 AVROBIO Inc. Launches to Develop Novel, Clinical-Stage Cell and Gene Therapies Targeting Immuno-Oncology and Rare Diseases
- 2/16 Merck's cholesterol meds Zetia, Vytorin lose final appeal for bigger CV market
- 2/16 BMS, Dana-Farber Launch Immuno-Oncology Collaboration
- 2/16 Massachusetts drops funding for opioid prescribing program as crisis rages
- 2/16 Express Scripts sees slow 2016 sales for new cholesterol drugs
- 2/16 15 Diseases and Ailments Marijuana May Help Fight
- 2/16 Cancer moonshot? It’s not rocket science!
- 2/16 Phase 3 Study Demonstrates Aranesp® Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
- 2/16 ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University to Advance Stem-to-T-Cell Program
- 2/16 Celator Pharmaceuticals Phase 3 Trial of VYXEOS™ Reaches Required Number of Events for Overall Survival Analysis
- 2/16 Seven Bridges raises $45M to fuel drive to be the backbone of large-scale genome projects
- 2/12 Novartis takes aim at Remicade market with EU biosim rights from Pfizer
- 2/12 Antidepressant Effexor Linked to Postpartum Bleeding in Study
- 2/12 Merck, Sun Pharmaceuticals terminate joint venture to develop branded generics for emerging markets
- 2/12 No joke: Opioid constipation drugs are serious business
- 2/12 The CNIO finds a potential therapy for the most aggressive type of lung cancer in preclinical models
- 2/12 Celsion Corporation Highlights Recent Pipeline Developments for its GEN-1 Immunotherapy Program
- 2/12 Biofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA
- 2/12 Forbes: The Risk Of Developing Dementia Is Declining
- 2/12 The Way Drugs Are Prescribed Is Changing
- 2/12 Incyte spurns Jakafi solid tumors, says 'IDO' to phase II combo program in cancer
- 2/11 Teva's Copaxone finally succumbs to copycats, putting a drag on 2015 sales
- 2/11 Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
- 2/11 Lannett Receives FDA Approval For Temozolomide Capsules
- 2/11 Puma Biotechnology’s ExteNET Phase III Study Published Online in The Lancet Oncology
- 2/11 Incyte to discontinue testing Jakafi in solid tumor cancers
- 2/11 Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance
- 2/11 TransCelerate BioPharma Introduces New Subsidiary BioCelerate to Increase Efficiencies in Preclinical Research
- 2/11 High-visibility Investments in M3 Biotechnology and its Drug to Reverse Alzheimer's, Parkinson's Lead Successful Funding Round
- 2/11 CTI-Baxalta Drug Withdrawn, Removing Potential Incyte Rival
- 2/11 Therapy advances in chronic myelogenous leukemia (CML)
- 2/10 Cancer Took His Wife. Now He's CEO Of One Of The Most Audacious Cancer Startups In Years
- 2/10 Biosimilars may expand drug access, reduce costs, but still much to learn
- 2/10 Melanoma Brings Immunotherapy to the Forefront, But Challenges Remain
- 2/10 Chugai's ALK Inhibitor "Alecensa®" Trial Stopped Early for Benefit
- 2/10 Big Pharma's new PCSK9, heart failure meds stuck in the slow lane. What gives?
- 2/10 FDA Lifts Heat Biologics Partial Clinical Hold
- 2/10 FDA puts full clinical hold on CTI BioPharma's blood cancer drug
- 2/10 OICisDifferent: The Drug Behind The Super Bowl 50 Constipation Ad
- 2/10 Sanofi Says 2016 Profit Won't Grow as Bestseller Lantus Fades
- 2/10 FDA Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma
- 2/9 Alkermes CEO Richard Pops Isn't Giving Up On Breakthrough Depression Drugs
- 2/9 ZIOPHARM Enrolled first patient in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy
- 2/9 Some heart drugs and antibiotics show effective in fighting cancer
- 2/9 DNAtrix's Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors
- 2/9 Top Senate Democrat grills HHS about opioid panel's alleged ties to industry
- 2/9 FDA seeks $5.1 billion for FY 2017, including funds to implement food safety law, improve medical product safety and quality
- 2/9 Novartis sets heart-drug price with two insurers based on health outcome
- 2/9 Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis
- 2/9 Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates
- 2/9 Clinical Trial Offers New Drug Combo to Fight Lung Cancer
- 2/8 8 developing healthcare trends
- 2/8 Pfizer builds on early Ibrance lead as Novartis, Lilly rivals inch closer
- 2/8 FDA delays decision on Duchenne drug but accepts info from Sarepta
- 2/8 Waiting for a true cancer ‘moonshot’
- 2/8 FDA Grants Breakthrough Designation to Immunomedics for Sacituzumab Govitecan for Treatment of Triple-Negative Breast Cancer
- 2/8 FDA declines to expand indication for Vertex's cystic fibrosis drug Kalydeco
- 2/8 AZ cancer immunotherapy combo impresses in lung cancer trial
- 2/8 The race for combined checkpoint inhibition in NSCLC
- 2/8 India's Pharmaceutical Market to Skyrocket from $20B to $55B by 2020
- 2/8 Benefits of pazopanib over sunitinib for renal cell carcinoma
- 2/5 AstraZeneca CEO still interested in M&A but he is getting very picky
- 2/5 FDA shoots down Vertex's latest bid for Kalydeco expansion
- 2/5 Celltrion's biosimilar of J&J's Remicade reviewed favorably by FDA staffers
- 2/5 Johnson & Johnson, ViaCyte testing possible diabetes cure
- 2/5 OSE Pharma Announces Company’s Global, Pivotal Phase 3 Trial for Tedopi® Immunotherapy in Non-Small Cell Lung Cancer
- 2/5 Harnessing the power of light to fight cancer
- 2/5 US Oncology Research Translational Oncology Program Enrolls 2,000th Patient in Leading-Edge Phase I Clinical Trials
- 2/5 The future of cancer treatment
- 2/5 Phase 3 Study of BLINCYTO® Met Primary Endpoint Of Overall Survival In B-Cell Precursor ALL
- 2/4 After The Martin Shkreli Circus, How Can We Fix Drug Pricing?
- 2/4 FDA panel backs game-changing cognitive claim for Lundbeck antidepressant Brintellix
- 2/4 Patent losses looming, AZ fights back with Brilinta, diabetes and China
- 2/4 Cellular Biomedicine Group Wins $43M Investment from Dangdai
- 2/4 Insurers sued for denying access to hepatitis C drugs
- 2/4 Califf, FDA top officials call for sweeping review of agency opioids policies
- 2/4 Immunotherapy Is ASCO's Advance of the Year
- 2/4 FDA Approves Merck’s Single-Dose EMEND® for Injection, in Combination with Other Antiemetic Agents
- 2/4 Tackling the Global Cancer Burden: A Conversation with NCI’s Dr. Ted Trimble
- 2/4 Mirvetuximab Soravtansine in Combination with Keytruda® (pembrolizumab) for the Treatment of Ovarian Cancer
- 2/4 Seven $1 billion-plus drugs seen reaching market in 2016
- 2/3 Sen. Ted Cruz Wants To Change The Way The FDA Approves Drugs
- 2/3 All wet: Novartis is slammed for ‘alarmist’ ad for heart failure drug
- 2/3 Gene therapy pioneer James Wilson uses CRISPR/Cas9 to target liver disease
- 2/3 Takeda ups bet on Mersana's armed antibodies to $1B-plus, snags lead drug rights
- 2/3 Precision oncology: origins, optimism, and potential
- 2/3 The promise and challenges of rare cancer research
- 2/3 Alectinib in crizotinib-resistant, ALK-positive NSCLC
- 2/3 Liquid cancer biopsy: the future of cancer detection?
- 2/3 Drugmakers target depression’s cognitive fog
- 2/3 Onetime party drug hailed as miracle for treating severe depression
- 2/2 Will Gilead Follow The Pfizer Game Plan For Sales Growth?
- 2/2 Documents Detail Price Hike Decisions by Turing, Valeant
- 2/2 Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
- 2/2 Glaxo socks more cash into immunotherapy bet
- 2/2 Purdue loses a battle in war against OxyContin generics
- 2/2 Conflicts Common Among FDA Hearing Speakers
- 2/2 Researchers identify potential targeted therapy for lung cancer using fly model
- 2/2 NSCLC: Bevacizumab Beyond Disease Progression After First-line Bevacizumab
- 2/2 Samsung Bioepis' newly approved Benepali likely to have faster uptake than biosimilar infliximab
- 2/2 The Business of Immuno-Oncology
- 2/1 The Peculiar Brilliance Of Donald Trump's Healthcare Strategy
- 2/1 New data boosts Novo against Sanofi in insulin-market fight
- 2/1 CRISPR Editing of Human Embryos Approved in the U.K.
- 2/1 Treating Alzheimer's with High Blood Pressure Drugs
- 2/1 Exelixis Announces Positive OR from A Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma
- 2/1 Aduro Biotech Receives $22.4 Million in Clinical Development Milestone Payments From Janssen
- 2/1 Rapastinel Receives Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD)
- 2/1 China’s diabetes boom promises $23 billion pot for drug makers
- 2/1 3 Key FDA Decisions Expected in February
- 2/1 In a world with no antibiotics, how did doctors treat infections?
- 1/29 Amgen beats in Q4 as established drugs come through
- 1/29 Strong Q4 showings for AbbVie abroad offset Humira, Viekira stumbles at home
- 1/29 Merck ushers in price war for hepatitis C medicines with new drug
- 1/29 The top 10 (possible) blockbusters that (might) launch this year
- 1/29 Ablynx receives 8 million euro milestone as Boehringer starts first patient study with bi-specific nanobody
- 1/29 Tricked-Out Immune Cells Could Attack Cancer, Spare Healthy Cells
- 1/29 Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD
- 1/29 FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4
- 1/29 FDA approves first drug to show survival benefit in liposarcoma
- 1/29 Merck launches hepatitis C drug price war
- 1/28 FDA approves first drug to show survival benefit in liposarcoma
- 1/28 Bristol-Myers immunotherapies soar, but Eliquis haul tops the charts
- 1/28 Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT for the Treatment of ADHD in Patients 6 Years and Older
- 1/28 Instead Of A 'Moonshot,' Cancer Research Needs Reasonable Regulation
- 1/28 FDA Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma
- 1/28 ArQule Provides Proprietary Pipeline Update for AKT Inhibitors
- 1/28 Incyte stops tests on Jakafi to treat colorectal cancer
- 1/28 CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early
- 1/28 Lynparza™ (olaparib) granted Breakthrough Therapy for treatment of BRCA1/2 or ATM gene mutated Prostate Cancer
- 1/28 Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of AML
- 1/28 The Battle Over CRISPR Could Make Or Break Some Biotech Companies
- 1/27 Trump crosses party lines to back Medicare drug-price negotiation
- 1/27 Science team says they've taken another step toward a potential cure for diabetes
- 1/27 'The first therapeutic use of CRISPR will be to treat an eye disease'
- 1/27 Lilly, BI approach CV-benefit label change for SGLT2 med Jardiance
- 1/27 First-in-Class, Rare Disease Drug Approvals Dominated in 2015: A Breakdown from FDA
- 1/27 STRIVE trial of enzalutamide Compared to bicalutamide in Castration-resistant Prostate Cancer
- 1/27 Giotrif® demonstrated superiority to Iressa® in reducing the risk of disease progression
- 1/27 Big Pharma's bet on Big Data creates opportunities and risks
- 1/27 Investigative Monoclonal Antibody Shows Activity in Metastatic Colorectal Cancer: Presented at ASCO-GI
- 1/27 Eli Lilly's baricitinib has potential, but uncertainty remains over first-line aspirations
- 1/26 Does Marketing Have Too Much Control In Big Pharma Clinical Trials?
- 1/26 Sanofi and Regeneron likely to cough up royalties to end Amgen's PCSK9 patent suit: Analyst
- 1/26 Amgen's Humira biosim is one step closer to FDA approval. But how close is it to market?
- 1/26 Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation
- 1/26 ImmunoGen Earns Milestone with a Phase 2 Clinical Study Designed to Support Anetumab Ravtansine Registration
- 1/26 Big Pharma's bet on Big Data creates opportunities and risks
- 1/26 KTB Ventures Joins $30M Series B Round In CARsgen
- 1/26 Codiak Biosciences raises another $61 million
- 1/26 UT Southwestern Scientists Synthesize Nanoparticles That Can Deliver Tumor Suppressors to Damaged Livers
- 1/26 Medivation Says FDA Places Investigational New Drug Application For MDV9300 On Partial Clinical Hold
- 1/25 FDA’s CDER Previews 2016 Guidance Agenda
- 1/25 Athenex Announces US FDA's IND Allowance of Oradoxel, the Proprietary Oral Form of Docetaxel
- 1/25 Dako Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma
- 1/25 BMS' Opdivo evens the score in melanoma with two new FDA green lights
- 1/25 FDA expands use of BMS' Opdivo, Yervoy combo
- 1/25 Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO GI 2016
- 1/25 OncoMed Shares Fall After Discouraging News on Pancreatic Cancer Drug
- 1/25 Vectibix Improves Overall Survival In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer
- 1/25 New Data Shows SGLT2 Inhibitors May Be Effective in Preventing Kidney Failure
- 1/25 China Is on a Quest to Develop New Billion Dollar Drugs
- 1/22 Is There Hope For Sarepta Therapeutics? Yes, A Bit
- 1/22 Amgen's Repatha wins first PCSK9 OK in Japan
- 1/22 Pfizer's Ibrance clears first hurdle to early access in U.K.
- 1/22 Benefits of cystic fibrosis drug ivacaftor reported in pre-school children for the first time
- 1/22 Two-Step Delivery Method Ups Cancer Drug’s Concentration In Tumors
- 1/22 Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Pancreatic Cancer
- 1/22 FDA expands use of Amgen's blood cancer drug Kyprolis
- 1/22 OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer
- 1/22 Slowing noted in growth of cancer expenditures
- 1/22 Sanofi layoffs expected as reorganization goes into effect
- 1/21 Improving CRISPR’s Cut-and-Paste Functionality
- 1/21 Agenus Announces Clearance of IND by the FDA for anti-CTLA-4 and anti-GITR Antibodies
- 1/21 Philogen Announces Commencement of Phase III Pivotal Trial in Melanoma
- 1/21 Immunotherapy Trial Demonstrates Encouraging Survival Rates in Patients with Metastatic Colorectal Cancer
- 1/21 Philogen Announces Exercise of Options With Pfizer Inc. for the Development of Multiple Antibody Drug Conjugates (ADCs)
- 1/21 AcelRx Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data
- 1/21 VIBERZI (eluxadoline) Phase III Trial Results Published in The New England Journal of Medicine
- 1/21 Alkermes' experimental depression drug fails to meet main goal in two late-stage studies; shares drop
- 1/21 Some Good News, Finally, for Zafgen’s Obesity Drug
- 1/21 Where Could Pfizer Be in 10 Years?
- 1/20 Solving Pharma's Shkreli Problem
- 1/20 Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals
- 1/20 BMS, Lilly, Sanofi and Novartis top Big Pharma's growth fortunes for next decade: Analysts
- 1/20 BIOCAD Announces the First Trastuzumab Biosimilar Approved by the Ministry of Health of the Russian Federation
- 1/20 Everolimus delays progression of neuroendocrine tumors
- 1/20 China's BeiGene pitches a $150M IPO to fund its cancer pipeline
- 1/20 AbbVie and Roche's cancer drug snags another 'breakthrough' tag
- 1/20 Biden pledges faster U.S. approval for cancer drug cocktails
- 1/20 Nanoparticles combine photodynamic and molecular therapies against pancreatic cancer
- 1/20 Eli Lilly files for FDA approval of baricitinib for moderately-to-severely active rheumatoid arthritis
- 1/19 A Medical Leader Steps Up To Defend Biopharma: Tom Stossel's 'Pharmaphobia'
- 1/19 GAO report hammers FDA for lax oversight on speedily approved drugs
- 1/19 Ofatumumab (Arzerra Injection)
- 1/19 Supreme Court declines to hear J&J appeal of Children’s Motrin lawsuit
- 1/19 Italy's Money-Back Guarantee for Cancer Treatments
- 1/19 Scientists call for more details about drug used in deadly French clinical trial
- 1/19 Big question for Pfizer: Will Enbrel's EU biosim bring on the pain?
- 1/19 Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma
- 1/19 Oncolytics Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer
- 1/19 Karyopharm Initiates Second Generation SINE™ Compound Clinical Trial in Multiple Myeloma
- 1/18 A sweeter treatment for breast cancer: Oxford scientists use sugar to deliver drugs
- 1/18 PD-L1 Inhibitor Active in Advanced Kidney Cancer
- 1/18 Patent Expirations Of Crestor And Zetia And The Impact On Other Cholesterol Drugs
- 1/18 Major drugmakers push back in U.S. price debate
- 1/18 Impax Receives Approval of EMVERM™ (mebendazole) Chewable Tablets, 100 mg
- 1/18 From fanciful to practical – AbbVie’s aggressive Humira defence begins to bear fruit
- 1/18 Samsung Gets European Approval for Enbrel Copy
- 1/18 Samsung Bioepis' biosimilar version of Enbrel approved in EU
- 1/18 Merck reaches $830M settlement in long-running Vioxx litigation
- 1/18 China’s diabetes boom promises $23 billion pot for drug makers
- 1/18 The Problem With The New Breast Cancer Screening Recommendations
- 1/14 Enzyme’s 3D Pose Could Improve Antibiotic Drug Discovery
- 1/14 FDA rejects drug for Duchenne muscular dystrophy
- 1/14 Is the cure for cancer real or rhetoric?
- 1/14 Can We Truly "Cure" Cancer?
- 1/14 Joe Biden's Mission To Cure Cancer Has A $5.2 Billion Head Start
- 1/14 Karyopharm Initiates Clinical Trial of Oral Selinexor in Advanced Liposarcoma
- 1/14 Interference Proceeding Likely to Prolong CRISPR Patent Case
- 1/14 GE Healthcare Joins Canadian Partners in Building Cell Technologies Center
- 1/14 Phase 2 Trial of Enzalutamide Compared to Bicalutamide in Metastatic Castration-Resistant Prostate Cancer
- 1/13 President Obama Taps Biden To Eradicate Cancer In State Of The Union Speech
- 1/13 Johns Hopkins flags another possible successor to 'Special K' for depression
- 1/13 Pfizer CEO: Allergan deal is 'a lot more about growth' than job cuts
- 1/13 New Bayer site to make traditional Chinese and Western consumer health meds
- 1/13 Esperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study
- 1/13 Statins Boost Abiraterone Activity in Prostate Cancer
- 1/13 Verseon Presents Data on a New Class of Anti-Coagulants at the 8th Biotech Showcase Conference
- 1/13 Taking drugs for depression linked to better diabetes control
- 1/13 AbbVie, Roche's venetoclax awarded priority review by FDA for chronic lymphocytic leukaemia
- 1/13 Biosimilars Are Coming After Big Pharma's Bottom Line
- 1/13 FDA Panel Favors Approval for Drug-Oozing Addiction Implant
- 1/13 Drug makers dismiss outrage over high prices as ‘abomination’
- 1/13 Chinese Drug Ingredient Supplier Draws 61 Complaints of Flaws
- 1/13 FDA nominee sails through Senate committee, but could a fish stand in his way?
- 1/12 One microcapsule could combine two drug ingredients when triggered at tumor site
- 1/12 Provectus Biopharmaceuticals Confirms First Patients Dosed in Trials of PV-10 for Melanoma
- 1/12 Pharma scandals spawn investor lawsuits at KaloBios, Sequoia
- 1/12 Nasdaq to Suspend KaloBios Pharmaceuticals, Inc. on January 13, 2016
- 1/12 Aurobindo Pharma Receives US Regulator's Nod for Generic Drug
- 1/12 U.S. justices reject Johnson & Johnson unit's anti-psychotic drug appeal
- 1/12 GlaxoSmithKline's Move To Drop Use Of Medical Experts Is Misguided
- 1/12 Organizational Changes Strengthen Leadership Team and Position Celgene for Long-Term Growth
- 1/12 Painkiller tapped to become future cancer-killer
- 1/12 Matthew Herper's 7 Thoughts On Today's Pharma & Biotech News
- 1/11 F-star Enters Into Collaborative Discovery & Development Agreement With AbbVie for Bispecific Antibodies in Immuno-oncology
- 1/11 Shire to Combine with Baxalta in Deal Valued at About $32 Billion
- 1/11 Juno Acquires Harvard Spinout, AbVitro, For $125M To Discover More Cancer Immunotherapies
- 1/11 GlaxoSmithKline's Move To Drop Use Of Medical Experts Is Misguided
- 1/11 Incyte Presents Significant Progress in its Development Portfolio
- 1/11 The Medicines Company Advances First-in-Class PCSK9 Synthesis Inhibitor for Atherosclerotic Cardiovascular Disease (ASCVD)
- 1/11 Price of prescription drugs rose over 10 percent in US last year
- 1/11 Pfizer Awards $46M in Financing to Four Early-Stage Companies
- 1/11 How Valeant Tripled Prices, Doubled Sales of Flatlining Drug
- 1/11 U.S. IND Becomes Active for BGB-A317, an Anti-PD-1 Monoclonal Antibody
- 1/8 Pfizer Taps Adaptive to Advance Immuno-Oncology Programs
- 1/8 Enumeral Presents Research Results for Novel Class of Anti-PD-1 Antibodies
- 1/8 OncoMed Announces Publication of Anti-RSPO Antibody Research in Cancer Research
- 1/8 Roche says encouraged by cancer drug atezolizumab study
- 1/8 Zymeworks Announces $61.5 Million Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody Therapeutics
- 1/8 New Germantown biotech nets $67 million from investors
- 1/8 Diabetes, Alzheimer’s Share Molecular Pathways, Part of Same Vicious Cycle
- 1/8 Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial
- 1/8 Dana-Farber Spinout C4 Inks $750M+ Collaboration with Roche
- 1/8 Special Report on the Future of Cancer Prevention Research Published in American Association for Cancer Research Journal
- 1/7 Daratumumab Data Published in The Lancet Shows Encouraging Efficacy in Heavily Pretreated and Refractory Multiple Myeloma
- 1/7 Higher Breast Cancer Rates Will Push Treatment Market Beyond $17 Billion by 2021
- 1/7 Exclusive License Agreement between Sloan Kettering and Juno Therapeutics for CAR T Cell Immunotherapy
- 1/7 Teva and Checkpoint Therapeutics Announce License Agreement for Oral PARP Inhibitor
- 1/7 Dana-Farber Spinout Grabs $73M, Plus Big Roche Deal, To Craft New Class Of Cancer Drugs
- 1/7 J&J signs deal with Chinese company for hepatitis B drug
- 1/7 Lab-Generated, Insulin-Producing Cells Prevent Onset of Diabetes
- 1/7 Caladrius Axing 40 Employees, Ending Phase III Study of Lead Candidate
- 1/7 High-Fidelity CRISPR-Cas9 Nucleases Virtually Free of Off-Target Noise
- 1/7 Valeant names Howard Schiller as interim CEO
- 1/6 CRISPR/Cas9 trifecta: Researchers correct genetic defect that triggers Duchenne muscular dystrophy
- 1/6 CEO Frazier expects Merck to be player in hep C market, M&A this year
- 1/6 U.K. Collaboration Aims to Accelerate CAR T-Cell Research
- 1/6 Roche Leads a $175 Million Investment in Flatiron Health
- 1/6 Eli Lilly, Pfizer, J&J, AbbVie Join $48M Bet On NYC Cancer Drug Startup
- 1/6 Valeant to appoint interim CEO as Pearson remains hospitalized: source
- 1/6 BeyondSpring to Present Plinabulin-Immune System Interactions at AACR’s 2016 Tumor Microenvironment Special Conference
- 1/6 Washington University Initiates IND of VS-6063 in Combination with Pembrolizumab and Gemcitabine in Pancreatic Cancer
- 1/6 Does Melatonin Really Help You Sleep?
- 1/6 New Weapons in the Fight Against Multiple Myeloma
- 1/5 Gilead wins speedy FDA review for latest hep C combo
- 1/5 Exelixis Announces Positive Results of the METEOR Phase 3 Pivotal Trial of Cabozantinib
- 1/5 Immunomedics Announces New Patent Covering the Use of Antibody-SN-38 Conjugates Combination
- 1/5 Aduro Biotech Expands Patent Portfolio With Key Newly Issued Composition and Methods Patents
- 1/5 Historic CRISPR Patent Fight Primed To Become Head-To-Head Battle
- 1/5 Lily Rises on Jardiance Market Share Gain as Outlook Disappoints
- 1/5 Gene-Editing Drugmaker Backed by Google, Gates Files for IPO
- 1/5 Genentech partner makes 1st Bay Area biotech IPO filing of 2016
- 1/5 Human Insulin Market Worth 39.13 Billion USD by 2020
- 1/5 10 Top 2016 Stock Picks From Goldman Sachs, Merrill Lynch and Other Key Analysts
- 1/5 The biggest winners--and losers--in the 2015 race for new drug approvals
- 1/5 2015 New Drug Approvals Hit 66-Year High!
- 1/4 FDA strengthens requirements for surgical mesh for the transvaginal repair of pelvic organ prolapse to address safety risks
- 1/4 STING Protein May Serve as Biomarker for Colorectal and Other Cancers
- 1/4 Shire could nab Baxalta for $32B this week: Bloomberg
- 1/4 Roche resolves patent war with India's Glenmark over generic Tarceva
- 1/4 New year, same strategy – Shire committed to Baxalta deal despite analyst and investor concerns
- 1/4 Branded and Generic APIs Look to Strong 2016
- 1/4 Gastric cancer treatment market to reach $4.4b by 2024
- 1/4 What's Up Next? Biotech And Pharma Predictions For 2016
- 1/4 The Top 5 Best Performing Biotech Stocks of 2015
- 1/4 Eight Milestones Of 2015 In The War On Cancer
- 12/30 Basilea provides clinical program updates
- 12/30 Cell-Free Protein Synthesis System Might Save Lives in Remote Locations
- 12/30 Mortality rates soar as critical access hospitals perform more inpatient surgeries
- 12/30 Critics continue pounding 21st Century Cures Act for threatening patient safety
- 12/30 Factors predicting low patient accrual in cancer clinical trials
- 12/30 Pfizer's breast cancer drug Ibrance may be effective against other types of cancer
- 12/30 Pennywise And Billion-Foolish: Troubling Data For Pfizer's Ian Read
- 12/30 Shkreli's Former Company KaloBios Files for Bankruptcy
- 12/30 Three Compelling Cancer Advances from 2015
- 12/30 Pneumonia-stricken Valeant chief takes medical leave of absence
- 12/29 CVD Risk Increased With Early vs Late-Onset Diabetes
- 12/29 The Price Keeps Falling For a Superstar Gilead Drug in India
- 12/29 ASCO Responds to Proposed Rules on 2017 Benefit and Payment Parameters
- 12/29 One of the coolest ideas ever to treat cancer is being developed right in Charlestown
- 12/29 Add-on ibrutinib increases response rates, PFS in patients with previously treated CLL, small lymphocytic leukemia
- 12/29 2015 in Biomedicine: Baby Engineering, Spray-On GMOs, and Cancer Cures
- 12/29 Baidu Teams Up with Medical Researchers to Fight Cancer
- 12/29 Alzheimer's player Anavex reveals SEC probe; shares dive
- 12/29 Valeant CEO Michael Pearson to take medical leave; shares fall
- 12/29 The CRISPR scientists who are altering genetic history
- 12/29 TapImmune moves forward with new drugs
- 12/28 Chimerix Antiviral Candidate Brincidofovir Fails Phase III Trial
- 12/28 Drug pricing will continue to loom large for pharma in 2016
- 12/28 Immunotherapy Is Game-Changer for Oncology—NSCLC, breast cancer, multiple myeloma all respond to checkpoint inhibitors
- 12/28 Pharmacyclics' 'miracle cure': A cancer drug
- 12/28 Rich Pharmaceuticals, Inc. Receives FDA Approval for a Phase 1/2 Study in AML & MDS
- 12/28 Immune Pharmaceuticals Announces Exclusive License to a Novel Bispecific Antibody Technology
- 12/28 Teva and Takeda reveal details of JV
- 12/28 Iran's Pharmaceutical Sector to Become a Pharma Powerhouse Post Sanction Era
- 12/28 India adds more cancer, HIV/AIDS drugs to essential medicines list
- 12/28 Biopharma’s Good, Bad, and Ugly of 2015
- 12/28 Gene Switch Controlled Kinetically, Not Thermodynamically
- 12/23 Amgen's PCSK9 outcomes trial to deliver data sooner than expected
- 12/23 Australia bets $1B on pricey hep C drugs in broad effort to eradicate the disease
- 12/23 Shkreli's troubles put attention on how drug industry conducts business
- 12/23 Aurobindo in advanced talks with European company to acquire permits for four biosimilars
- 12/23 Exelixis Completes Submission of NDA for Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
- 12/23 Seattle Genetics and BMS initiated Phase 1/2 Clinical Trial of ADCETRIS® in Combination with Opdivo® in Non-Hodgkin Lymphoma
- 12/23 Transgene Announces Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer
- 12/23 The Role Of Big Pharma In Neglected Diseases
- 12/23 Medicare drug costs rose sharply in 2014
- 12/23 China: Baidu teams up with PUMC on esophageal cancer research
- 12/23 Surge in Prescription Costs Hit Medicare in 2014
- 12/22 FDA approves new orphan drug to treat pulmonary arterial hypertension
- 12/22 FDA approves Zurampic to treat high blood uric acid levels associated with gout
- 12/22 IMDC Model Valid in First-Line Pazopanib for mRCC
- 12/22 Further Research Into Checkpoint Blockade for Upper Tract Urothelial Cancers Needed
- 12/22 Merck KGaA and Pfizer Advance Two Additional Phase III Trials of Avelumab
- 12/22 Independent group says new Glaxo asthma drug far too expensive
- 12/22 CardioBrief: Rumors Denied on PCSK9 Brain Infection Risk
- 12/22 BeyondSpring Granted CTA by CFDA to Initiate China Arm of Global Phase III Trial of Plinabulin
- 12/22 Aduro Biotech Initiated Phase 1 Study of ADU-741 for the Treatment of Prostate Cancer
- 12/22 Baxalta and Momenta target AbbVie's blockbuster with positive biosim data
- 12/22 Martin Shkreli Is Removed as C.E.O. From Another Company, KaloBios
- 12/21 Sorry, pharma. Martin Shkreli's disgrace won't take the heat off your pricing
- 12/21 AstraZeneca's Acerta deal could put the hurt on AbbVie's Imbruvica
- 12/21 Alnylam Files IND for ALN-GO1, a RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
- 12/21 What’s Next for KaloBios Pharmaceuticals Inc?
- 12/21 Afatinib a Better Choice for EGFR-mutated Lung Cancer in First-line Treatment
- 12/21 Merck’s KEYTRUDA® Improves Survival Compared to Chemotherapy in Previously-Treated Non-Small Cell Lung Cancer
- 12/21 Lion Biotechnologies Enters Clinical and Preclinical Research Collaboration With MedImmune
- 12/21 BI 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
- 12/21 5 Can't-Miss Drug Approvals of 2015
- 12/21 The U.S. Pays a Lot More for Top Drugs Than Other Countries
- 12/21 Merck's Vytorin Study Epitomizes Inherent Risks Of Major Clinical Trials
- 12/18 FDA permits marketing of fecal continence restoration system
- 12/18 U.S. shells out more for top-selling drugs, even when rebates are factored in: Bloomberg
- 12/18 FDA expands melanoma indication for Merck & Co.'s Keytruda
- 12/18 FDA delays decision on Intercept's liver disease drug OCA
- 12/18 ‘I want what Jimmy Carter had’: Patients clamor for the president’s cancer drug
- 12/18 Here Is What Martin Shkreli Said About Prosecutors Before He Was Arrested
- 12/18 Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
- 12/18 Initiation of Sulfatinib Phase III Registration Study in Neuroendocrine Tumor Patients
- 12/18 The Logic in AstraZeneca’s Buying Spree
- 12/18 AstraZeneca Chases AbbVie, Cheaply
- 12/9 U.S. drug approvals hit record level as biotech stocks sag
- 12/9 Breast Cancer Drugs Battle Disease's Return
- 12/9 Women's Sex Drive Pill Is Defended by FDA, With Caveats
- 12/9 FDA allows marketing of cooling cap to reduce hair loss during chemotherapy
- 12/9 FDA approves first recombinant von Willebrand factor to treat bleeding episodes
- 12/9 Venetoclax Is A Powerful New Kind of Cancer Drug Effective In Chronic Lymphocytic Leukemia
- 12/9 One-two punch of palbociclib and paclitaxel shows promise against advanced breast cancer
- 12/9 Bio-Path Holdings’ Data from Phase I and Safety Segment of Phase II Clinical Trials
- 12/9 Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA® Data
- 12/9 This Pharma Company is Rebounding From a Major Scandal
- 12/8 FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients
- 12/8 Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed CLL
- 12/8 Amgen and Regeneron Face Declining PCSK-9 Prescription Volumes
- 12/8 The 3 Most Important Drugs in Gilead Sciences' Pipeline
- 12/8 Initiation of Fruquintinib Phase III Registration Trial in Non-small Cell Lung Cancer
- 12/8 Bluebird Bio's Lost Year
- 12/8 Drug shows potential as safe and effective for most prevalent form of adult leukemia
- 12/8 BeiGene Presents Clinical Data for BTK Inhibitor BGB-3111 at 57th ASH Annual Meeting
- 12/8 Successful Vaginal Pain Drug Trial Sends TherapeuticsMD Soaring
- 12/8 Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA™ (bendamustine hydrochloride) Injection
- 12/7 J&J blood thinner under review for trial overseen by FDA nominee Califf
- 12/7 Clinton keeps heat on drug industry with tax proposal for inversion deals
- 12/7 Merck immunotherapy Keytruda shows promise in multiple myeloma trial
- 12/7 AbbVie Reports Phase 2 Results of Venetoclax in Relapsed/Refractory CLL Patients with 17p Deletion
- 12/7 AbbVie, J&J leukemia drug cuts death risk vs chemo in new patients: study
- 12/7 Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for Non Hodgkin Lymphoma (NHL)
- 12/7 For Hepatitis C Drugs, U.S. Prices Are Cheaper Than In Europe
- 12/7 Eli Lilly ends development of insulin peglispro
- 12/7 Early Weight Loss With Saxenda Predicts More
- 12/7 The 5 Most Expensive Medications Medicare Covers
- 12/4 Cancer drug prices vary across the globe as countries strike deals with Big Pharma: Study
- 12/4 Harnessing The Immune System To Fight Cancer: 'Now We Can Offer Hope'
- 12/4 Sun Pharma Gets FDA Approval for Generic of Novartis' Gleevec
- 12/4 Gene therapy cures adult leukemia patient in China
- 12/4 Adding Olaratumab to Chemo Improves Survival in Soft Tissue Sarcoma
- 12/4 Study shows abiraterone acetate is useful even in most aggressive prostate cancers
- 12/4 'Nanobombs' might deliver agents that alter gene activity in cancer stem cells
- 12/4 AbbVie's NDA for Once-Daily Viekira Pak Accepted by FDA
- 12/4 BRCA1 is back in the spotlight, this time for Alzheimer's disease
- 12/4 Pfizer CEO: "What We're Doing May Fundamentally Save The Industry"
- 12/3 Kalydeco, For Cystic Fibrosis, Wins First Annual Forbes Breakthrough Drug Award
- 12/3 FDA delays proposed rule on safety warnings for generic drugs again
- 12/3 NICE balks at Alexion's $552K price for orphan drug Strensiq
- 12/3 Lyxumia's CV results may help Sanofi's case for approval, but they won't score it points against SGLT2s
- 12/3 Merck CEO: In Healthcare, We Cannot Afford to Fail
- 12/3 Health Spending in U.S. Topped $3 Trillion Last Year
- 12/3 Kite Pharma and GE Global Research Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies
- 12/3 3-D Printers Can Now Make Pills That Deliver A Customized Dose Of Medicine
- 12/3 Repatha Vs. Praluent: Will Amgen's Patents Decide The Race For The Prevailing PCSK9 Inhibitor?
- 12/3 Novo's Victoza beats SGLT2 inhibitors in lowering blood sugar
- 12/2 Novo touts SGLT2-topping data for blockbuster Victoza
- 12/2 GSK jumps on the 'smart inhaler' bandwagon with Ellipta sensor deal
- 12/2 Delivering Drugs via Internal Swimming Devices
- 12/2 Zafgen Discloses Second Patient Death in Obesity Trial
- 12/2 Why Blocking microRNAs in Triple Negative Breast Cancer Is so Difficult
- 12/2 Kite Pharma Initiates the ZUMA-3 registration Study of KTE-C19 for Relapsed or Refractory (r/r) ALL in Adult
- 12/2 Stopping ovarian cancer in its tracks: An antibody may help patients heal themselves
- 12/2 50 Most Innovative Companies
- 12/2 Broad, MIT scientists overcome key CRISPR-Cas9 genome editing hurdle
- 12/2 Cancer cells can poison normal cells
- 12/2 Clozapine Benefits Those With Tx-Resistant Schizophrenia
- 12/1 Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti
- 12/1 New Approach Described for Eliminating Cancer Stem Cells
- 12/1 Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial
- 12/1 ImmunoCellular Therapeutics Establishes Agreement with EORTC for ICT-107 Phase 3 Registrational Trial in Glioblastoma
- 12/1 NCCN Collaborates With Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer
- 12/1 Brent Saunders Softens His View On Research With Jim Cramer On 'Mad Money'
- 12/1 Teva, Takeda enter partnership targeting Japan's growing generic drug market
- 12/1 Eisai and Arena Announce FDA Acceptance of NDA for Extended Release Formulation of Lorcaserin
- 12/1 James Allison on the Future of Checkpoint Inhibitors in Melanoma
- 12/1 Is Big Data analytics the secret to improving cancer treatment?
- 11/30 Pfizer Does Not Need A Merger, It Needs A Rebellion
- 11/30 Under Pressure: Gearing Up for a Year of Regulatory Convergence
- 11/30 CRISPR Reduces Cancer Genomes to Bare Essentials
- 11/30 4 steps to take the healthcare continuum into the age of value-based care
- 11/30 FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma
- 11/30 Bristol-Myers Squibb's Opdivo May Change How We Treat Pancreatic Cancer
- 11/30 Beijing aims to refill medicine chest with 'Made in China' drugs
- 11/30 Martin Shkreli's new pharmaceutical company is up another 80%
- 11/30 Antibody-drug compounds and immunotherapy to treat breast cancer
- 11/30 FDA declines expanded approval for Bristol-Myers' Opdivo drug
- 11/25 Mount Sinai team maps a key combo role for new checkpoint drugs
- 11/25 Novo Nordisk Joins Ablynx in Up-to-$399M+ Nanobody Alliance
- 11/25 U.K. investigators publish small, promising study of Victoza for NASH
- 11/25 Turing offers discounts instead of cutting controversial list price on Daraprim
- 11/25 Drug Helps Those With Tough-to-Treat Schizophrenia: Study
- 11/25 Uni-Bio Science Acquires Global Rights to Type 2 Diabetes Drug Mitiglinide from Jiangsu Hansoh Pharmaceutical
- 11/25 Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To FDA
- 11/25 Meaningful Endpoints for Immuno-Oncology Trials
- 11/25 The first-in-class compound halts tumor growth by disrupting protein production
- 11/25 'Real-World' Melanoma Treatment Patterns Similar to Trials
- 11/24 FDA approves Portrazza to treat advanced squamous non-small cell lung cancer
- 11/24 JAMA: Gilead, AbbVie hep C meds cost-effective even in early stages of liver disease
- 11/24 Trump, Clinton lash out at Pfizer over Allergan deal agreement
- 11/24 FDA approves expanded use of Bristol-Myers' skin cancer drug
- 11/24 HER2-Enriched Molecular Subgroup Highly Sensitive to Breast Cancer Regimens
- 11/24 Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs PFS but not OS
- 11/24 Genmab's lymphoma project flops in Phase III with Novartis holding the bag
- 11/24 The Pfizer-Allergan Deal Shouldn’t Be Just About Tax Inversion
- 11/24 Google Glass used to help restore blood flow in chronically blocked coronary artery
- 11/24 Gaining a Fuller Understand of Neurotoxicity From CAR T Cell Therapy
- 11/24 Novartis' Entresto garners European approval for chronic heart failure
- 11/23 GSK, Idera Partner on Third-Gen Antisense Drugs for Renal Disease
- 11/23 CTI BioPharma Initiates Rolling Submission of NDA for Pacritinib for the Treatment of Patients with Myelofibrosis
- 11/23 FDA approves Opdivo to treat advanced form of kidney cancer
- 11/23 NewLink Genetics Announces Clinical Data on Indoximod/Temozolomide Combination in Glioblastoma
- 11/23 Roche buoyed by early data on atezolizumab in advanced melanoma
- 11/23 Value-based purchasing scores remain volatile
- 11/23 Aduro reports Q3 revenue of $19.15 million
- 11/23 Merger Math: Is There Anything Left For Pfizer To Cut At Allergan?
- 11/23 Merck Announces Initial Results for KEYTRUDA® in Combinations with Three Investigational Studies
- 11/23 Bumper haul of expensive new drugs heads to U.S. and Europe
- 11/23 Brain Cancer Vaccine Gets Better With Time, As Celldex Shows Survival Edge
- 11/20 FDA approves Ninlaro, new oral medication to treat multiple myeloma
- 11/20 Novel Nanocarriers Open Door to Better Treatment for Brain Cancer
- 11/20 Checkpoint Inhibitors Stir Up Excitement in RCC Treatment
- 11/20 Angiochem Reports Positive Clinical Data with ANG1005 in Breast Cancer Patients with Leptomeningeal Carcinomatosis
- 11/20 UPDATE 1-Shkreli leads group to buy 70 pct shares in KaloBios, named CEO
- 11/20 Brand-Name Drugs Increase Cost But Not Patient Satisfaction
- 11/20 Pfizer Deal Could Be Worth $187 Million for Allergan's Saunders
- 11/20 Exclusive: Pfizer negotiating 2-3 percent Allergan break-up fee - sources
- 11/20 AstraZeneca, Sanofi agree to share compounds under open innovation model
- 11/20 First-to-market opportunity in allogeneic CAR-T therapy too good an opportunity to miss, says Pfizer
- 11/19 Is Bayer Still a Buyer?
- 11/19 Shkreli among Investors Buying Majority of KaloBios Shares
- 11/19 Express Scripts rolls out value-based pricing for cancer meds
- 11/19 Mallinckrodt boosts buyback plan amid news of a 2,000% price hike on infant drug
- 11/19 Allergan CEO Brent Saunders: Here's What I Really Think About R&D
- 11/19 Sofosbuvir Plus Velpatasvir Promising for Patients With Hepatitis C Virus and Decompensated Liver Disease: Presented at Liver Meeting
- 11/19 Meta-Analysis: Rosuvastatin May Be Superior for Plaque Regression
- 11/19 Medicaid denies half of prescriptions for new hepatitis C drugs, Penn study finds
- 11/19 FDA Clears New, Easy-To-Use Version of Heroin Antidote
- 11/19 Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
- 11/19 New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melanoma
- 11/19 Investigational immunotherapeutic increased bladder cancer survival
- 11/18 RNA-Based Drugs Turn CRISPR/Cas9 On and Off
- 11/18 Drug maker in trouble with FDA for failing to report side effects
- 11/18 CRISPR/Cas9 2.0: Research team offers an upgrade to gene editing tech
- 11/18 Advera Health: Novartis, GSK asthma meds linked to more side effects than Merck drugs
- 11/18 U.K. cost gatekeeper says 'no' to Amgen's PCSK9 cholesterol fighter Repatha
- 11/18 Enumeral Reports Allosteric Anti-PD-1 Antibodies Can Elicit an Additive Effect on T Cell Activation in Combination with a Marketed Anti-PD-1 Antibody
- 11/18 Acute Kidney Injury Linked to BRAF Inhibitors in Melanoma
- 11/18 Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI® (crizotinib) to Chemotherapy in NSCLC
- 11/18 Global drug spending to hit $1.4 trillion in 2020: IMS
- 11/18 Merck KGaA and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic MCC
- 11/17 J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex price
- 11/17 Pharma faces 'challenging and prolonged' reforms in China, with pricing power at risk
- 11/17 FDA Accepts for Priority Review the sBLA for Opdivo (nivolumab) in Patients with Advanced Renal Cell Carcinoma
- 11/17 Infinity Announces Completion Of Target Enrollment In DUO™, A Phase 3 Study Evaluating Duvelisib In CLL
- 11/17 Medivir terminates the ADAM8 inhibitor project for pancreatic cancer
- 11/17 Non-Small Cell Lung Cancer Market to Grow from $6.9 Billion in 2014 to $10.9 Billion by 2021
- 11/17 U.S. court rules Helsinn and Roche’s patent claims for Aloxi are valid and infringed
- 11/17 Will Allergan Chief Saunders Become A Research Convert As Pfizer CEO?
- 11/17 The World's Biggest Consumers Of Antidepressants
- 11/17 Korean Billionaire's Gains Pile Up as Pharma Stock Surges 900%
- 11/17 Coffee-drinkers less likely to die from heart disease, suicide, diabetes or Parkinson's
- 11/16 Top 20 generics companies by 2014 revenue
- 11/16 FDA nominee Robert Califf must prove his independence from industry
- 11/16 FDA approves Darzalex for patients with previously treated multiple myeloma
- 11/16 Clovis Craters on Lung Cancer Drug-Review Delay, Shares tumbled 67%
- 11/16 Clinical Trials: The Elephant in the Room
- 11/16 Gilead’s Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy in Phase 3 Study of Patients with Relapsed CLL
- 11/16 Tragara and Lee's Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize TG02 in Greater China Market and South East Asia
- 11/16 Array BioPharma And Pierre Fabre Announce Collaboration For Two Novel Oncology Products, Binimetinib And Encorafenib
- 11/16 5 Drugs That Are the Face of Prescription Drug Reform
- 11/16 Panel recommends Merck & Co continue cholesterol drug study
- 11/16 FDA approves Baxalta's drug for rare bleeding disorder
- 11/13 Alzheimer’s Drug Candidate Also Reverses Effects of Aging
- 11/13 FDA approves new pill to treat certain patients with non-small cell lung cancer
- 11/13 DelMar Pharmaceuticals Presents Data Summarizing the Potential of VAL-083 as a New Treatment Option for Resistant Cancers
- 11/13 Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy Strategy
- 11/13 Gilead scores additional indications for Harvoni in hep C, HIV patients
- 11/13 The promise and problems of drug-finding apps
- 11/13 Drugmakers Kept One-Third of Trial Results Secret, Study Finds
- 11/13 Biogen making risky shift to Alzheimer’s drugs
- 11/13 U.S. FDA approves Gilead's hepatitis C drug for expanded use
- 11/13 Cornell engineers develop 'killer cells' to destroy cancer in lymph nodes
- 11/13 Better View of Immune Landscape Leads to New Targets for Cancer Therapy
- 11/12 Roche cutting 1,200 jobs in major shift in producing drugs
- 11/12 LEO Pharma Buys Astellas' Dermatology Business for $725M
- 11/12 Drug makers kept many clinical trial results a secret: study
- 11/12 Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA (OTX-DP) for Treatment of Allergic Conjunctivitis
- 11/12 Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation
- 11/12 Dendrimer technology gets a grip on cell proteins, could improve cancer treatment
- 11/12 Immune Design Announces Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients With Soft Tissue Sarcoma
- 11/12 ImmunoCellular Therapeutics Enters into Agreement with MD Anderson to Advance Stem-to-T-Cell Program
- 11/12 ADI-PEG 20 Shows Robust Clinical Activity in Malignant Plural Mesothelioma and NSCLC When Combined with Chemotherapy
- 11/12 WebMD will compete with physician social networks with new Medscape virtual consult app
- 11/11 WuXi, Lilly Partner to Develop Dyslipidemia Candidate in China
- 11/11 Express Scripts cuts off pharmacy that sells drugs for Horizon Pharma
- 11/11 KIT team points pancreatic cancer therapy toward clinical trials
- 11/11 Microbiome study highlights bacterial strategy for treating severe diarrhea
- 11/11 MD Anderson group tracks 'modest' impact of lymphoma drug
- 11/11 World-first blood cancer drug trial reveals life-changing results
- 11/11 Sophiris's prostate drug meets main goal in late-stage study
- 11/11 AstraZeneca lupus drug impresses in mid-stage trial
- 11/11 The UK's Accelerated Access Review: Time to Dust Off Old Reports?
- 11/11 Pfizer, Allergan Said to Discuss Making Saunders CEO in Deal
- 11/10 With $10B deal hunt, Amgen looks even more like Big Pharma
- 11/10 Celyad completes 30-day safety follow-up of first patient cohort in NKG2D Car T-Cell phase I trial
- 11/10 You Are Not Paying For The Cholesterol Drugs Of Others -- Yet!
- 11/10 Astellas to Acquire Ocata Therapeutics for $379M
- 11/10 FDA approves Cotellic as part of combination treatment for advanced melanoma
- 11/10 Groups with ties to pharma want to block CDC opioid prescribing guidelines
- 11/10 UPDATED: J&J slapped with $1.75M verdict in Risperdal breast growth case
- 11/10 Novo Nordisk diabetes drug fails to help heart failure -study
- 11/10 Diabetes Drug Reduces Risk of Heart Failure and May Prevent It, Study Shows
- 11/10 Two Drugs—FDA Approved for Arthritis and Blood Disorders—May Help Fight Baldness
- 11/9 First-in-class Antibody-Drug Conjugate Shows Significant Clinical Benefit Against Metastatic Triple-negative Breast Cancer
- 11/9 Immunomedics Reports Improved Progression-Free Survival Results With Sacituzumab Govitecan in Triple-Negative Breast Cancer
- 11/9 Lilly Licenses Ignyta's Cancer Compound Taladegib for Up-to-$53M+
- 11/9 With just 50 reps to Takeda's 900, Vivus' Qsymia beats Contrave on Q3 sales
- 11/9 Sanofi's back-to-growth strategy fails to impress analysts
- 11/9 NewLink Genetics Announces Promising Clinical Data on Indoximod at the Society for Neuro-Oncology Annual Meeting
- 11/9 Investigational AKT Inhibitor AZD5363 is Active Against Multiple Tumor Types With AKT1 E17K Mutations
- 11/9 Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Presented At AACR-NCI-EORTC International Conference
- 11/9 Dr. Reddy's Falls Most in 11 Years on U.S. FDA Warning
- 11/9 Incyte Plummets After Cancer Drug Helps Fewer Than Expected
- 11/6 Pharm Exec's 2016 Pipeline Report
- 11/6 Chi-Med Initiates Sulfatinib U.S. Clinical Trials
- 11/6 Viralytics and Merck & Co., Inc.to Collaborate on Combination CAVATAK(TM) and KEYTRUDA(R) in Lung and Bladder Cancer
- 11/6 Dr. Reddy's feels FDA heat, gets warning letter for three plants
- 11/6 Sanofi, Lexicon Partner to Develop Phase III Diabetes Drug
- 11/6 They said no to company-mandated flu shot and now fear firing. Here's why
- 11/6 AstraZeneca boosts cardiovascular, metabolic disease portfolio with $2.7-billion purchase of ZS Pharma
- 11/6 Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting
- 11/6 CytomX and MD Anderson Cancer Center Enter Into Strategic Collaboration for Probody-Enabled CAR-NK Cell Therapies
- 11/6 Cancer Treatment in a Painless Patch
- 11/5 FDA approves new treatment for HIV
- 11/5 Why Breakthroughs Like PCSK-9 Drugs Burst Onto The Scene At Once
- 11/5 Tracking Cancer Progression in Real Time Using Circulating DNA
- 11/5 HPV vaccine not linked to chronic pain or fainting: European regulators
- 11/5 Does AstraZeneca own the color purple? On a pill, yes, the company contends
- 11/5 Esperion Therapeutics Announces Two Oral Presentations for ETC-1002 at the American Heart Association Scientific Sessions 2015
- 11/5 Once a Takeover Candidate, Vertex Is Now Looking for Deals
- 11/5 GPhA tallies savings from generic drug use
- 11/5 FDA approves Nucala to treat severe asthma
- 11/5 AstraZeneca lifts full-year guidance as Brilinta sales grow in third quarter
- 11/5 Lenalidomide + Rituximab: First Line in Mantle Cell Lymphoma
- 11/4 Vertex sees dealmaking, CF meds as defenses against would-be buyers
- 11/4 Merck KGaA, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Advanced NSCLC
- 11/4 Americans are spending more on prescription drugs than in other countries
- 11/4 Oxford team spotlights promise of AstraZeneca drug in targeting cancers
- 11/4 JAK inhibitors target senescent cells in aging study
- 11/4 Incyte revenue projections for cancer drug Jakafi rise
- 11/4 Nanotechnology May Lead to Tumor-Priming Strategy in Pancreatic Cancer
- 11/4 Immunitor unveils Phase II trial of hepcortespenlisimut-L at the Society of Immunotherapy of Cancer
- 11/4 BMS and the Johns Hopkins Enter Into a Collaboration for Immuno-Oncology Rare Population Malignancy Research
- 11/4 Nearly 60 percent of Americans — the highest ever — are taking prescription drugs
- 11/3 Enumeral Reports Anti-PD-1 Antibodies Elicits Higher T Cell Activation than Currently Marketed Anti-PD-1 Antibodies
- 11/3 Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers
- 11/3 Personalized Medicine Starts Predicting Personalized Side Effects
- 11/3 Sanofi, BioNTech Launch Up-to-$1.5B Immuno-Oncology Alliance
- 11/3 CRISPR-Cas9 Utility Broadened by Increasing Its Targeting Range
- 11/3 Valeant’s unsavory ways are a lesson for everyone
- 11/3 Pfizer flirted with a GSK megabid, but got rejected: FT
- 11/3 UPDATED: Feds arrest, charge ex-Warner Chilcott sales execs. Should pharma be worried?
- 11/3 Irish Drug Maker Shire Agrees to Buy Dyax in Deal Worth Up to $6.5 Billion
- 11/3 CMS final rule on biosimilar reimbursement another win for innovators
- 11/2 Will Acquiring Allergan Impact Pfizer's R&D?
- 11/2 Will a compounded version of Martin Shkreli’s drug really make a difference?
- 11/2 AstraZeneca sees red over a ‘purple pill’ and sues a generic drug maker
- 11/2 FDA cites Pfizer for shortfalls at Chinese manufacturing plant
- 11/2 Kite Pharma Initiates ZUMA-1 Phase 2 in Patients With Refractory Non-Hodgkin's Lymphoma (NHL) to Support Registration of KTE-C19
- 11/2 Merck Receives Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) in Advanced Colorectal Cancer
- 11/2 Apixaban Reduces Risk of Major Bleeding Better Than Other Anticoagulants for Non-Valvular AF: Presented at CHEST
- 11/2 Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3
- 11/2 4 Key FDA Decisions Expected in November and December
- 11/2 Factbox: Drugs to watch at Roche, Sanofi and GSK
- 11/2 Shire to buy Dyax for up to $6.5 billion, expanding hereditary angioedema portfolio
- 10/30 Celgene’s VIDAZA® (Azacitidine for Injection) Approved by the European Commission as New Treatment for AML
- 10/30 Patent challenger Bass wins IP reviews for Celgene, Shire meds
- 10/30 Humira gives AbbVie solid Q3 support, but biosimilars loom
- 10/30 Regeneron Announces EU Approval of EYLEA (aflibercept) Injection for Visual Impairment Secondary to Myopic Choroidal Neovascularization
- 10/30 4 medical innovations that will revolutionize healthcare in 2016
- 10/30 Doctors, Patients Battling Sky-High Drug Price Increase
- 10/30 Why the FDA Is Worried About Chinese Drugs in Your Medicine Cabinet
- 10/30 The Q&A: Pfizer/Allergan – five key questions
- 10/30 CVS Health, Express Scripts drop specialty pharmacy distributor tied to Valeant
- 10/30 he top 10 biopharma pipeline disasters of 2015
- 10/29 'Milestone' prostate cancer drug
- 10/29 Aduro Biotech Receives Milestone Payment From Janssen for Acceptance of IND for ADU-214 in Lung Cancer
- 10/29 With Allergan Deal, Pfizer Would Flee The U.S. Over Taxes
- 10/29 Q3 beats on sales, earnings ready Amgen for biosimilar attack
- 10/29 FDA expands use of Bristol Myers' cancer drug Yervoy
- 10/29 Glaxo's Profit Exceeds Estimates as HIV Drug Sales Soared
- 10/29 GSK chief: We don't need a breakup or a Pfizer deal. Just look at ViiV's sales surge
- 10/29 Pfizer, Allergan say in talks on merger
- 10/29 Novartis' Entresto slow out of the gates, but long-term potential remains undiminished
- 10/29 Cellular Biomedicine Presented Phase IIa Results From CAR-T CD20 for Advanced B-cell Non-Hodgkin Lymphoma
- 10/29 CRISPR’s Epigenetic Aim Is True
- 10/29 Igenica, MedImmune to Partner on Anti-SAIL ADCs
- 10/29 Cancer: Organ-seeking vesicles
- 10/28 JAK inhibitors demonstrate fresh promise in restoring hair growth
- 10/28 Drug-device combo from Wyss takes a new approach on treating stroke
- 10/28 Howard Hughes researcher IDs a new target for autoimmune disease
- 10/28 Boehringer Ingelheim's Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab
- 10/28 Intercept Pharmaceuticals Announces Results of Phase 2 Trial of OCA in NASH Patients in Japan
- 10/28 Old drug may help keep Alzheimer's patients out of nursing homes
- 10/28 Study: Mobile health app promotes self-management in spina bifida
- 10/28 Gilead posts surge in Q3 profit, revenue; full-year sales outlook lifted again
- 10/28 Celgene Patent on Revlimid to Be Reviewed on Bass Challenge
- 10/28 FDA approves first-of-its-kind product for the treatment of melanoma
- 10/27 The eyes have it: FTC probes Valeant over contact lens
- 10/27 Merck's Remicade bleeds market share to biosims, but Januvia holds its own
- 10/27 GSK’s Advair Diskus achieves primary endpoint in LABA safety study of patients with asthma
- 10/27 Celator® Pharmaceuticals Announces VYXEOS™ (CPX-351) Selected As Best Nanomedicine Product
- 10/27 4 Blockbuster Drugs Whose Sales Could Easily Double
- 10/27 U.S. FDA Approves BELBUCA™ (buprenorphine) Buccal Film for Chronic Pain Management
- 10/27 Sanofi's new CEO set to deliver revival plan after falling diabetes sales
- 10/27 FDA sees no heart risks from Novartis' Parkinson's drug
- 10/27 75 USFDA approvals received by Indian drug makers in current fiscal
- 10/27 EMA signs up to AdisInsight on a four-year deal
- 10/26 Valeant To Double Its R&D -- To Do What?
- 10/26 Prescription drug price hikes are slowing this year… so far, anyway
- 10/26 How much can J&J make of Yondelis' long-sought FDA approval?
- 10/26 FDA Review Found No Increased Cardiovascular Risks
- 10/26 Merck & Co. Discounts Remicade by 25% in U.K. to Fend Off Rivals
- 10/26 Amgen wins EU green light for first virus-based cancer drug
- 10/26 Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy
- 10/26 GlaxoSmithKline CEO cites innovation as best strategy to combat pricing pressure
- 10/26 FDA panel backs approval of AstraZeneca's investigational gout-related drug lesinurad
- 10/26 FDA approves new therapy for certain types of advanced soft tissue sarcoma
- 10/23 Novartis wins European recs for a pair of new Cosentyx uses
- 10/23 Witty insists GSK's safe approach, backed by innovative pipeline, is the way to success
- 10/23 Inspirion Receives FDA Approval for MorphaBond extended-release tablets CII, an Opioid Analgesic Formulated with Abuse-Deterrent Properties
- 10/23 Martin Shkreli Won't Suffer Because Of That $1-A-Pill Competitor. Here's Why
- 10/23 GE Sees Cell Therapy Industry's Sales at $10 Billion by 2021
- 10/23 Leo Pharma’s Enstilar approved by FDA
- 10/23 What makes Valeant different than innovative biopharmaceutical companies?
- 10/23 Allergan, Endo, Horizon Pharma move to distance themselves from allegations against Valeant
- 10/23 FDA approves new treatment for rare metabolic disorder
- 10/23 FDA approves new treatment for advanced pancreatic cancer
- 10/23 FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
- 10/22 ImmunoGen, Roche gastric cancer drug fails study
- 10/22 Exelixis Initiates Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer
- 10/22 AstraZeneca, Lilly Expand Immuno-Oncology Collaboration
- 10/22 How to decide if a cancer drug is worth the cost NCCN’s Carlson explains
- 10/22 Zafgen Announces Beloranib Program Update
- 10/22 FDA approves new drug to treat hyperkalemia
- 10/22 Novartis, Google Creating Lenses that Correct Vision in a Millisecond
- 10/22 The Biotech Scramble for Big Money in Muscular Dystrophy Drugs
- 10/22 This Is The Man In India Who Is Selling States Illegally Imported Execution Drugs
- 10/22 Researchers using Google Glass to develop system to help children with autism
- 10/21 23andMe's Triumph -- And The Long Road Ahead
- 10/21 Shares in Valeant fall up to 28 percent after report questions link to specialty pharmacies
- 10/21 GE Sees Cell Therapy Industry's Sales at $10 Billion by 2021
- 10/21 Gene therapy for brain protein boosts memory in aged mice
- 10/21 Georgetown researchers flag success of pilot Parkinson's drug study
- 10/21 Clinton urges FDA, FTC to take action against questionable pharma pricing
- 10/21 Synta halts study of lung cancer treatment, stock plummets
- 10/21 A Wonder Drug's Frightening Side Effect
- 10/21 Merck's Shorter-Treatment Hep C Drugs Work in Mid-Stage Trial
- 10/21 Drug Firms Buy Pricey Vouchers to Speed Products to Market
- 10/20 The problem with using surrogate markers to approve cancer drugs
- 10/20 Medicare covered $4.6B in hep C scripts for H1, and Gilead's the big winner
- 10/20 FDA-Accelerated Ca Drugs Don't Get Adequate Follow-Up
- 10/20 TSRI Scientists Find Way to Make Leukemia Cells Kill Each Other
- 10/20 Subanalyses of Phase III SELECT trial of Eisai’s Lenvima Provides Further Evidence in People with Advanced Thyroid Cancer
- 10/20 Going After Customized Lung Cancer Vaccines, Gritstone Grabs $102M
- 10/20 One year after FDA nod, Eli Lilly's Trulicity launches first consumer campaign
- 10/20 Clinton Targets Drug Companies, But Still Takes Their Donations
- 10/20 US oncologists assess the value of cancer drugs – five key questions
- 10/20 Microsoft, Johns Hopkins University to redesign ICU health information technology
- 10/19 One Stage: $700 Billion Of Pharma Firepower
- 10/19 Daiichi plans its second big round of US job cuts this year
- 10/19 Influential cancer group rolls out first set of 'affordability' ratings on cancer drugs
- 10/19 Discovery opens door to new strategy for cancer immunotherapy
- 10/19 FDA Grants Inotuzumab Ozogamicin Breakthrough Status for ALL
- 10/19 Can A Cancer Drug Reverse Parkinson's Disease And Dementia?
- 10/19 Zafgen Future Imperiled by New Safety Risk Tied to Obesity Drug
- 10/19 AstraZeneca diabetes drug combination faces delay after FDA rebuff
- 10/19 Merrimack Pharmaceuticals called ’innovative,’ as company waits on first potential FDA approval
- 10/19 FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa
- 10/15 In The R&D Drug Lottery, Biopharma Is Putting Most Chips On The Big Prizes
- 10/15 Valeant hit with two federal subpoenas as drug-price controversy rages on
- 10/15 Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C
- 10/15 Tumor Models Bridge Mouse-Human Gap
- 10/15 Lilly and Incyte's oral arthritis drug tops Humira in a big Phase III trial
- 10/15 Another setback for Pfizer's Xeljanz
- 10/15 FDA declines to expand approval of Pfizer arthritis drug
- 10/14 Beyond bird poop: FDA warns drug maker over disturbing record keeping
- 10/14 Zafgen discloses patient death in Phase III trial for Prader-Willi syndrome drug beloranib, shares fall
- 10/14 Want to Bet Immunotherapy Will Revolutionize Cancer? There's an ETF For That
- 10/14 Poorly designed animal experiments in the spotlight
- 10/14 Selective reporting of primary, secondary endpoints common in randomized oncology trials
- 10/14 Eli Lilly starts online course in drug development
- 10/14 Red Wine May Boost Heart Health in T2D Patients
- 10/14 FDA grants priority review of Daklinza in difficult-to-treat patients
- 10/14 Ex-FDA inspector reveals the tricks to avoid 483 observations during your next facility audit
- 10/14 Is This Cancer Treatment Worth It? New Tool Offers Patients Data
- 10/13 Four Reasons Drugs Are Expensive, Of Which Two Are False
- 10/13 Novo Nordisk chief Sørensen tops world's-best CEO ranking
- 10/13 Is Turing illegally thwarting generic copycats? New York antitrust squad wants to know
- 10/13 WuXi PharmaTech Launches Mobile OncoWuXi, the World's First App for Accessing Oncology Models
- 10/13 New Study Published in Cell Reports Highlights Indoximod, Demonstrates the Key Role of IDO in Both Local and Systemic Immunosuppression
- 10/13 Savolitinib Completes Enrolment for Phase II Clinical Trial in Papillary Renal Cell Carcinoma
- 10/13 Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer
- 10/13 J&J third-quarter sales miss mark, hurt by strong dollar
- 10/13 Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab)
- 10/13 Did Amgen Waste $300 Million In Buying A Flawed Heart Drug?
- 10/13 Lilly's Struggle To Come Back: Can Once-Great Pharma Companies Be Great Again?
- 10/12 Eli Lilly's Good Cholesterol Drug Went Bad. Here's What That Means For Pharma
- 10/12 A Lilly cholesterol drug flops, so what are the implications? What the wags say
- 10/12 Hong Kong's cheaper prices for Sovaldi, Herceptin and other drugs draw throngs
- 10/12 BMS' Opdivo gets a jump on Keytruda with another early FDA approval
- 10/12 Here’s the Terrible Habit Killing 30 Percent of This Country’s Young Men
- 10/12 Celsion Announces Impressive Preclinical Data for its GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® for Ovarian Cancer
- 10/12 Pharma's largest licensing deals in Q3 – the summer lull and a market pullback don't stop pharma's deal making
- 10/12 Halaven® (Eribulin) Demonstrates Overall Survival Benefit in Rare Soft Tissue Sarcoma Sub-types
- 10/12 Eli Lilly expands cancer tie-up in fast-growing China market
- 10/12 Eli Lilly, Innovent Biologics expand China-focused agreement to include immuno-oncology
- 10/9 FDA expands approved use of Opdivo in advanced lung cancer
- 10/9 U.K. cost watchdog gives second thumbs-up in a week to Merck's Keytruda for skin cancer
- 10/9 How healthcare providers can make value-based care turn a profit
- 10/9 China’s High Cancer Drug Prices Create a Lucrative Market in Hong Kong
- 10/9 A Pediatric Cancer Drug Three Decades in the Making
- 10/9 AstraZeneca Temporarily Halts Cancer Drug Combination Trials
- 10/9 Aduro Biotech Receives Milestone Payment From Janssen for Submission of IND for ADU-214 in Lung Cancer
- 10/9 High-Dose Methotrexate With Leucovorin Rescue Is Promising for Tough-to-Treat CNS Syndromes: Presented at ECTRIMS
- 10/9 U.S. cancer doctors drop pricey drugs with little or no effect
- 10/9 Neurocrine Biosciences reports positive late-stage data for tardive dyskinesia drug NBI-98854
- 10/9 Roche reports positive data from three studies for experimental MS drug ocrelizumab
- 10/8 Senator asks FTC to investigate Shkreli for antitrust violations
- 10/8 Oncologists' pricing pushback mounts as docs snub costly me-too drugs
- 10/8 Will approval of Aristada broaden the long-acting injectable antipsychotic market?
- 10/8 Merck/Pfizer's avelumab fast-tracked for rare skin cancer
- 10/8 The FDA is lukewarm on those hyper-valuable vouchers for fast drug reviews
- 10/8 Nobel discoveries on DNA repair now fuelling cancer drug research
- 10/8 Synta Pharmaceuticals Announces Formation of Expert Oncology Panel
- 10/8 Sunesis Announces Anticipated Submission of European Marketing Authorization Application for Vosaroxin in AML Before Year End
- 10/8 With FDA 'breakthrough' in hand, Eli Lilly shoots for accelerated abemaciclib OK
- 10/8 Two-hit therapy for breast tumors using approved drugs looks promising in animal study
- 10/7 Rutgers researchers make headway with an HDAC inhibitor for Alzheimer's
- 10/7 Alzheimer's: Investigators spotlight a pathway for amyloid beta clearance
- 10/7 Bristol takes aim at three more hep C niches with Daklinza
- 10/7 Drug makers donate millions to fight California discount initiative
- 10/7 Eravacycline Data Supporting Activity Against Multidrug-Resistant Gram-Negative Bacteria to be Presented at IDWeek 2015
- 10/7 A New Way to Define Value in Drug Pricing
- 10/7 Express Scripts Says It Will Cover 2 New Cholesterol Drugs
- 10/7 Targeted chemotherapy shows early signs of slowing tumor growth with less toxicity
- 10/7 Catching cancers when they are small still makes a difference to survival
- 10/7 Seattle Genetics Announces Phase 1/2 Clinical Trial of ADCETRIS® in Combination with Opdivo® in Second-line Hodgkin Lymphoma
- 10/7 FDA puts clinical hold on Advaxis cancer drug
- 10/7 Merck KGaA and Pfizer Announce Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma
- 10/6 Company Run By 30-Year-Old Former Hedge Fund Manager Starts Study To Get Its Alzheimer's Drug Approved
- 10/6 FDA approves new injectable drug to treat schizophrenia
- 10/6 Roche CEO: Big Data needs Big Pharma, and vice versa
- 10/6 Investors cheer as Arena forces out CEO and cofounder
- 10/6 India calls ban on 700 generic drugs "unwarranted"
- 10/6 FDA awards priority review to Bristol-Myers Squibb's filings for hepatitis C drug Daklinza
- 10/6 Why the FDA should take more chances on riskier drugs
- 10/6 How Martin Shkreli prevents generic versions of his pricey pill
- 10/6 Amicus Therapeutics Plunges on Delay in NDA Submission
- 10/6 Abcam’s New Anti-PD-L1 Antibody Enables Deeper Insights into Cancer Immunology Research
- 10/6 Roche says data shows Cotellic combination therapy effective
- 10/5 FDA marketing police most likely to slap pharma for risk-info omissions
- 10/5 ViewPoints: Gilead’s next ‘Wave’ of HCV regimens leaves room for competition
- 10/5 Novartis biosimilar copycat takes aim at Amgen's drug Enbrel
- 10/5 Chasing a ghost: Why is FDA guidance on biosim interchangeability taking so long?
- 10/5 5 Big FDA Decisions Expected in October
- 10/5 Oncobiologics Announces ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial
- 10/5 Revealed: how AstraZeneca avoids paying UK corporation tax
- 10/2 FDA approves Keytruda for advanced non-small cell lung cancer
- 10/2 Merck's Keytruda snags FDA approval for NSCLC, but label is narrow
- 10/2 Novartis targets Amgen's Enbrel with second biosimilar app
- 10/2 Massive, unexpected drug price increases are happening all the time
- 10/2 FDA Hits Pfizer Subsidiary With Second Form 483 in Five Years
- 10/2 Nab-Paclitaxel Shows Benefit in Advanced Melanoma
- 10/2 Teva to Buy Rimsa for About $2.3 Billion
- 10/2 Not done yet, Hillary Clinton airs pharma-focused ad starring Turing CEO
- 10/2 FDA grants priority review to defibrotide for hepatic veno-occlusive disease
- 10/2 Effectiveness of Talk Therapy Is Overstated, a Study Says
- 10/1 FDA Approves Nivolumab/Ipilimumab Combination for BRAF Wild-Type Melanoma
- 10/1 Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers
- 10/1 Novartis stacks up more data for lucrative Cosentyx expansion
- 10/1 U.K. patient group demands government override Roche's Kadcyla patents
- 10/1 U.S. FDA Approves JUVEDERM ULTRA XC for Use in Lips
- 10/1 The contentious gene editing field gets a tech upgrade. What now?
- 10/1 Ozanezumab Yields Disappointing Results for Treating Amyotrophic Lateral Sclerosis: Presented at ANA
- 10/1 New cholesterol drugs won't be budget busters: Express Scripts
- 10/1 Trashed Tests Put FDA on Notice as China Pushes Drug Exports
- 10/1 Cancer Immunotherapy: Where We Are And Where We're Going
- 9/30 FierceBiotech's 2015 Fierce 15
- 9/30 How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says
- 9/30 Infinity Announces Enrollment Of 120th Patient In Phase 2 DYNAMO™ Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma
- 9/30 Clovis Oncology Announces Regulatory Milestones for Rociletinib in the Treatment of Advanced NSCLC
- 9/30 Novartis CEO: Here's How We'll Get Cheap Medicine To Poor Countries
- 9/30 Lilly/Incyte unveil more PhIII success for RA drug baricitinib
- 9/30 FDA will review Sanofi's diabetes drug lixisenatide
- 9/30 Which Big Pharma Will Grab the Lion’s Share of the Cancer Immunotherapy Market?
- 9/30 Eight big questions in cancer research
- 9/30 CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute to Develop Novel CAR-T Technology
- 9/29 Real Precision Medicine Requires Real Access To Patient Data
- 9/29 FDA permits marketing of new laser-based hearing aid with potential for broad sound amplification
- 9/29 Who's most at risk if the U.S. cracks down on prices? Gilead, Celgene top the list
- 9/29 Hedge fund manager Kyle Bass escapes sanctions in drug patent case
- 9/29 Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours
- 9/29 Dr. Reddy’s rebooting biosimilars play
- 9/29 3 Biotech Stocks Short-Sellers Have Targeted the Most
- 9/29 Biotech stocks dive as lawmakers take aim at Valeant for drug price hikes
- 9/29 Hillary Clinton Proposes Drugmakers Fund Their Own Generic Competition
- 9/29 Cellular Biomedicine Group Announces Positive Results From CAR-T EGFR Immunotherapy in Advanced Relapsed/Refractory Patients With Solid Tumors
- 9/29 Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer
- 9/29 ZS-9 Rapidly Normalises Serum Potassium in Patients With Heart Failure, Hyperkalaemia: Presented at HFSA
- 9/28 Top 10 Pharma Firms of 2015
- 9/28 How much more does the U.S. pay for drugs? Up to 10 times more, report says
- 9/28 OncoSec Announces Positive Results from Phase II Trial of ImmunoPulse IL-12 in Merkel Cell Carcinoma
- 9/28 VBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)
- 9/28 Clinical Data Presented On Binimetinib And Encorafenib In Melanoma
- 9/28 Genentech Presents Positive Results from Pivotal Study of Investigational Immunotherapy Atezolizumab in Specific Type of Advanced Bladder Cancer
- 9/28 In A First, Kidney Cancer Drug Extends Survival
- 9/28 Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057
- 9/28 Boehringer’s Giotrif demonstrates superior survival over Roche’s Tarceva for lung cancer patients
- 9/28 Differences Found in Smokers, Nonsmokers Who Develop Lung Cancer
- 9/28 Eli Lilly CEO John Lechleiter discusses company’s troubled past, optimistic future
- 9/28 Allergan Launches Generic Version of INVEGA® (paliperidone)
- 9/28 The Best-Selling Drugs in the World By 2020
- 9/25 AbbVie scraps Galapagos deal to focus on own arthritis drug
- 9/25 Roche is 'well placed' for U.S. pricing tussle, CEO says
- 9/25 Alexion sues Canada over Soliris price cut attempt as drug cost debate explodes on center stage
- 9/25 Shire chalks up victory in Vyvanse patent battle
- 9/25 ImmunoCellular Therapeutics Awarded $19.9 Million Grant from California Institute for Regenerative Medicine (CIRM)
- 9/25 'Remote control' of immune cells opens door to safer, more precise cancer therapies
- 9/25 Extending overall survival is less important than quality of life and disease stability
- 9/25 Novartis CEO talks about drug costs, paying doctors and ‘doing the right thing’
- 9/25 Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis
- 9/24 My Lunch With Shkreli: What We Should Learn From Pharma's Latest Monster
- 9/24 Invictus Oncology Presents Data on IO-125, Novel Supramolecular Therapeutic at ASCO Breast Cancer Symposium, 2015
- 9/24 Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist
- 9/24 Concert shares soar as it bests Vertex cystic fibrosis drug in Phase 1 trial
- 9/24 The little-known FDA program that's driving drug prices higher
- 9/24 CTI heads to the FDA with its Baxalta-partnered cancer drug
- 9/24 Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action
- 9/24 Chemotherapy-Free Regimen Feasible for Acute Promyelocytic Leukemia
- 9/24 Atara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia
- 9/24 Long-Term Ibrutinib Data Show Durable Responses in Untreated and Relapsed/Refractory CLL
- 9/24 Amgen/Allergan's Avastin biosimilar hits PhIII targets
- 9/24 Concerns over FDA's increasing use of expedited development and approval pathways
- 9/24 Some pharma senior citizens still work overtime
- 9/23 Even With Concessions, Martin Shkreli Still Gets A Massive Price Hike For Daraprim
- 9/23 An arthritis drug demos potential to help reverse Alzheimer's disease
- 9/23 Stanford team creates a better viral vector to deliver drug payloads
- 9/23 AbbVie has plenty of cost-cutting room if Humira sales hit the skids: analyst
- 9/23 The Shkreli scandal leaves a big mess for biotech to clean up
- 9/23 Avanir Pharmaceuticals Announces Phase II Study Results Showing AVP-923 Significantly Reduced Agitation in Patients with Alzheimer's Disease
- 9/23 CTI BioPharma To Submit NDA For Pacritinib In Q4 Based Primarily On Data From Single Pivotal Persist-1 Trial
- 9/23 Most patients will experience a misdiagnosis in their lifetime
- 9/23 OncoRx Pharmaceuticals Announces Treatments for Therapy-resistant Tumors
- 9/23 Heron Therapeutics shares jump after pain drug succeeds in trial
- 9/23 Exclusive: Americans overpaying hugely for cancer drugs - study
- 9/23 OncoGenex's drug misses the mark in pancreatic cancer
- 9/22 FDA approves new oral medication to treat patients with advanced colorectal cancer
- 9/22 Valeant's latest tax-cutting tactic, courtesy of Luxembourg
- 9/22 Perrigo Announces FDA Approval and Launch of the AB Rated Generic Version of BenzaClin Topical Gel
- 9/22 NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors
- 9/22 Lower doses of heart meds save lives: study
- 9/22 Thanks, Turing. Your 5000% price hike puts pharma in the election hot seat
- 9/22 Gilead's Hepatitis C Drug Works Against All Strains in Trial
- 9/22 Stanford team re-engineers virus to deliver therapies to cells
- 9/22 Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients
- 9/22 AstraZeneca taps crowd sourcing to find cancer drug cocktails
- 9/21 FDA awards 18 grants to stimulate product development for rare diseases
- 9/21 New ulcerative colitis data could help Pfizer's Xeljanz pick up the pace
- 9/21 MerLion's Finafloxacin Shown to be More Efficacious than Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections
- 9/21 BGB324 Enhances Immune Checkpoint Inhibitor Efficacy in Preclinical Cancer Models
- 9/21 Genmab's Arzerra gets six-month review for maintenance CLL
- 9/21 Female Libido Pill Caused Dissent in FDA Ranks, Memo Shows
- 9/18 Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
- 9/18 FDA asks Pfizer for Zoloft label update highlighting birth defect risks
- 9/18 Novartis CEO stands by emerging markets even as China sales continue to sink
- 9/18 Biothera’s Imprime PGG Cancer Immunotherapy Drug Activates Dendritic Cells, Leading to Enhanced T Cell Expansion and Cytokine Production
- 9/18 Intas Pharma expects US approval for Neulasta biosimilar this year
- 9/18 Allergan and Richter's antipsychotic gets FDA OK but faces stiff competition
- 9/18 Senators tell FDA to pick up the pace on biosimilar guidelines
- 9/18 Advaxis therapy improves survival rates in cervical cancer patients
- 9/18 One Biotech CEO's Plan To Slash The Cost Of Cancer Immunotherapy
- 9/18 NIH takes next steps in Obama's Precision Medicine plan
- 9/18 Pfizer Weighing FDA Request to Change Zoloft's Warnings
- 9/17 Shocking Result: Diabetes Drug Saves Lives, But Not By Treating Diabetes
- 9/17 Friday Five – The week in pharma
- 9/17 NICE turns down pancreatic cancer drug Abraxane
- 9/17 Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas
- 9/17 Biothera's Imprime PGG Enhances Anti-Tumor Activity of the Innate Immune System's Macrophages
- 9/17 Henry Gosebruch, A 42-year old Rising Star at JPMorgan, Is Departing for AbbVie
- 9/17 How much is first-to-market worth? There's a formula for that
- 9/17 Can-Fite Bio shares surge about 40% as liver drug gets FDA fast track designation
- 9/17 FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer
- 9/17 Alzheimer's disease consists of 3 distinct subtypes, according to UCLA study
- 9/17 FDA Advisory Panel Recommends Approval of Flu Vaccine for Older Patients
- 9/17 Aerie Pharmaceuticals' eye drop succeeds in late-stage study
- 9/16 Robert Califf Could Transform The FDA -- The Right Way
- 9/16 Controversial resveratrol triggers new headlines--this time for Alzheimer's
- 9/16 Will payers make SGLT2 moves on Jardiance CV data? Not just yet
- 9/16 Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal
- 9/16 EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients
- 9/16 Nanoparticle biointerfacing by platelet membrane cloaking
- 9/16 Nanotechnology: Platelet mimicry
- 9/16 Small Protein Engineered to Target PD-L1 is More Potent Than Anti-PD-L1 Antibody Immunotherapeutic
- 9/16 Amgen bets up to $1.7B on Xencor's antibody technology
- 9/16 Roche says biotech 'bubble' pushes midsize buys out of reach
- 9/16 Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from FDA for Advanced Renal Cell Carcinoma (RCC)
- 9/16 Obama Nominates Duke Researcher Robert Califf to Lead FDA
- 9/15 Drug Discovery Tutorial: Immuno-Oncology Landscape Expands
- 9/15 Double discovery boosts quest for leukaemia cures
- 9/15 Combining epigenetic therapies with immunotherapies likely to improve cancer patient outcomes
- 9/15 FDA issues orders that will stop further U.S. sale and distribution of four R.J. Reynolds Tobacco Company cigarette products
- 9/15 AbbVie edges closer to Imbruvica deal payoff with another FDA filing
- 9/15 GW Pharmaceuticals Announces Positive Proof of Concept Data in Schizophrenia
- 9/15 FDA Approves Octapharma’s NUWIQ for the Treatment of Adults and Children with Hemophilia A
- 9/15 Sanofi's combination diabetes drug hits goal in second late-stage trial
- 9/15 First Biosimilar of a Biologic Drug Reaches U.S.
- 9/15 HIV Prevention Pill 100 Percent Effective in Trial, Researchers Say
- 9/15 Panel backs aspirin for heart health in only certain adults
- 9/14 Advera Health Analytics: Merck statins linked to more muscle side effects than rest of class
- 9/14 Diabetes rivalries get more complicated with new FDA warning on J&J's Invokana
- 9/14 Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX
- 9/14 Amgen seeks FDA approval for monthly dosing option for Repatha
- 9/14 FDA advisers side against Purdue's new painkiller, citing dosing dangers
- 9/14 Collegium's painkiller gets green light from FDA panel
- 9/14 AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia
- 9/14 Cetuximab Finds Niche in Non-Small Cell Lung Cancer
- 9/14 Compound Shows Modest Activity in Platinum-Resistant Ovarian Cancer
- 9/14 Johnson & Johnson CEO prescribes innovation for all that ails big pharma
- 9/14 NantWorks Enters into Exclusive License Agreement with Amgen to Target Cancer c-Met Receptor
- 9/11 China: Present for the Journey
- 9/11 AstraZeneca picks up discarded Amgen plant as part of its biologics expansion
- 9/11 FDA warning on J&J's Invokana adds more complexities to diabetes drug battles
- 9/11 Price Soars For Key Weapon Against Heroin Overdoses
- 9/11 FDA panel recommends not approving Purdue's opioid painkiller
- 9/11 Proteus, Otsuka submit first commercial drug with built-in sensor to FDA
- 9/11 Frontline Treatment Approaches in Advanced RCC
- 9/11 PhRMA Reports 836 Medicines and Vaccines in Development to Treat Cancer
- 9/11 Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation
- 9/11 Incyte files $1 billion claim over cancer drug
- 9/11 AstraZeneca nabs priority review voucher as Wellstat bags FDA OK
- 9/10 BioCancell Receives FDA Fast Track Designation for BC-819 for Treatment of Bladder cancer Patients
- 9/10 The FDA takes important steps in modernizing the food safety system
- 9/10 ViewPoints: ‘You get what you pay for’ – Biogen hopes not with Mitsubishi’s S1P receptor agonist
- 9/10 OncoMed Pharmaceuticals Announces Presentation of Tarextumab Small Cell Lung Cancer Data at the 16th World Conference on Lung Cancer
- 9/10 Study finds seeds of Alzheimer's may have spread in medical procedure
- 9/10 Getting Ahead with Modafinil: Is the Hottest New Smart Drug Safe?
- 9/10 Survival Not Improved by Adjuvant Bevacizumab in NSCLC
- 9/10 Immunomedics’IMMU-132 Encouraging in Previously-Treated Metastatic Lung Cancer
- 9/10 Discontinuing Nexavar leads to increased survival in HCC
- 9/10 Survival Trends Higher With Necitumumab in EGFR FISH–Positive Squamous NSCLC
- 9/9 Is Axovant's Alzheimer's Drug The Real Deal, Or A Phantasm?
- 9/9 Roche CEO: Despite China worries, emerging markets will continue to deliver growth
- 9/9 GlaxoSmithKline's hopes flag as Breo flunks COPD outcomes study
- 9/9 Health Activist Yentas: PCSK9s Imjproperly Priced; Should Be 85% Cheaper
- 9/9 Cancer Symptoms For Women And Men That You Should Absolutely NEVER Ignore
- 9/9 Five Prime Therapeutics Initiates Patient Dosing in Phase 1a/1b Trial Evaluating the Immunotherapy Combination of FPA008 and OPDIVO (nivolumab) in Six Tumor Types
- 9/9 Aduro enters clinical trial agreement to evaluate a combination of two novel cancer immunotherapies for treating ovarian cancer
- 9/9 Drugs behave as predicted in computer model of key protein, enabling cancer drug discovery
- 9/9 U.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
- 9/9 FDA Grants Genentech’s Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer
- 9/9 Immunocore's IMCgp100 Accepted by EMA for Adaptive Pathway Pilot Programme
- 9/8 24 Pharma And Biotech Giants Graded And Ranked
- 9/8 Novartis CEO: Payers not sold on performance pricing yet, but that'll change
- 9/8 Roche CEO lashes out at U.K.'s 'stupid' move to stop paying for a dozen-plus cancer meds
- 9/8 PCSK9 Inhibitor Therapies Face Pricing Pressures
- 9/8 Janssen’s myeloma drug daratumumab wins FDA priority review
- 9/8 Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells
- 9/8 Endocyte Announces Final Overall Survival Results From Phase 2b TARGET Trial in Non-Small Cell Lung Cancer Patients
- 9/8 Two pivotal trials for Bristol-Myers’ Opdivo show sustained survival results in patients with previously treated squamous NSCLC
- 9/8 Opdivo plus Yervoy effective first-line in lung cancer
- 9/8 Yabao and University of South Australia partner to develop new treatments for cancer
- 9/4 FDA's Hot August
- 9/4 Biotech Positioning for Boom Times and Beyond
- 9/4 Treatment of Schizophrenia With Aripiprazole Results in Greater QOL Improvements vs Paliperidone: Presented at ECNP
- 9/4 FDA approves longer-term use of AstraZeneca blood thinner Brilinta
- 9/4 Novartis wins EU approval for multiple myeloma drug Farydak
- 9/4 Mushroom Powder Shows Potential in Prostate Cancer
- 9/4 Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint
- 9/4 Moody's: Outlook for global pharmaceutical industry shifts to positive on successful product launches
- 9/4 MD Anderson adds Cellectis to a crush of immunotherapy collaborations
- 9/4 2014 Record Year for Antisense RNAi Therapeutics Deals
- 9/4 China Resilient: New Pharma Survey Offers Highly Positive Outlook
- 9/3 Novartis' LCZ696 scores another victory with early-access blessing in U.K.
- 9/3 GSK inks exclusive vaccines deal with new GlycoVaxyn affiliate
- 9/3 Scientists turn to aspirin to turbo-charge cancer immunotherapy
- 9/3 FDA Grants QIDP Designation and Fast Track Status to TP-271
- 9/3 Study supports watch-and-wait approach for many prostate cancers
- 9/3 Amgen and UCB's Osteoporosis Drug Bests Lilly's Forteo in Study
- 9/3 Report: Real-world Blincyto spending likely to fall far short of Amgen's $178K list price
- 9/3 First U.S. Biosimilar on Sale Now. Amgen cannot stop imminent sale of Neupogen copycat: appeals court
- 9/3 Gene variant linked to a 10-year delay in Alzheimer's onset
- 9/3 Some leukemia patients see durable results from Novartis's CTL019 CAR-T therapy
- 9/2 FDA approves new drug treatment for nausea and vomiting from chemotherapy
- 9/2 Ziopharm tests new approach to engineering CAR-Ts for solid tumors
- 9/2 More grist for PCSK9 fight as Amgen sets up EU to pay about half as much as U.S.
- 9/2 Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To EMA
- 9/2 Bristol-Myers Makes $150M Bet on Promedior, Fibrosis Drug
- 9/2 Are Statins Bad For Me? Personalized Medicine Can't Yet Say
- 9/2 Europe gets Amgen cholesterol drug for 50-60 percent of U.S. price
- 9/2 Waltham biotech gets FDA approval for drug to treat nausea after chemo
- 9/2 FOLFOXIRI Plus Bevacizumab Feasible for Some with Colorectal Cancer
- 9/2 Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody
- 9/1 BMS, AbbVie nab 'breakthrough' tag for multiple myeloma-fighting antibody
- 9/1 ESC: AstraZeneca gets more backing for long-term Brilinta use
- 9/1 Google, Sanofi team up to improve diabetes care
- 9/1 FDA accepts for priority review BLA for Bristol-Myers and AbbVie’s Empliciti to treat multiple myeloma
- 9/1 Dabrafenib/Trametinib Combo Granted EU Approval for Advanced Melanoma
- 9/1 Should riskier drugs be approved for lethal diseases?
- 9/1 'Eat me' signal whets appetites for tumor-devouring dendritic cells
- 9/1 Newly engineered CAR T cells can better discriminate between cancer and normal cells
- 9/1 Biotech Firms Need Innovation Strategies: Celgene, Genzyme, and Monsanto Show How Innovation Strategies Can Pay Off
- 9/1 Pfizer resists calls for greater clinical trial transparency
微信号：美中药源